Document:

Unassociated Document

    Exhibit
      10.1

     

    SUBSCRIPTION
      AGREEMENT

     

    SUBSCRIPTION
      AGREEMENT (“Agreement”),
      dated
      as of July 2, 2007, by and between ACCBT Corp., a corporation duly
      incorporated under the laws of the British Virgin Islands (“ACCBT”),
      and
      Brainstorm Cell Therapeutics Inc., a corporation duly incorporated under the
      laws of the State of Delaware, USA (“Company”).

     

    WHEREAS,
      the
      Investor (as defined below) wishes to subscribe for and purchase, and the
      Company wishes to issue and sell, upon the terms and conditions stated in this
      Agreement, (i) up to 27,500,000 shares of the Company’s common stock, par value
      0.00005 per share (“Common
      Shares”),
      at an
      aggregate subscription price of up to $5.0 million (“Maximum
      Subscription Price”)
      for
      all possible subscription shares hereunder (“Subscription
      Shares”),
      and
      (ii) warrants in substantially the form attached hereto as Exhibit
      A
      (“Warrants”),
      to
      acquire up to such additional number of Common Shares as provided below (as
      exercised, collectively, the “Warrant
      Shares”).

     

    WHEREAS,
      contemporaneously with the execution and delivery of this Agreement, the parties
      hereto are executing and delivering a Registration Rights Agreement,
      substantially in the form attached hereto as Exhibit
      B
      (the
“Registration
      Rights Agreement”)
      pursuant to which the Company will provide certain registration rights with
      respect to the Registrable Securities (as defined in the Registration Rights
      Agreement) under the 1933 Act (as defined below) and the rules and regulations,
      promulgated thereunder and applicable state securities laws. 

     

    NOW,
      THEREFORE, the
      Company and the Investor hereby agree as follows:

     

    
      	1.  	
              DEFINITIONS

            

    

     

    Other
      than certain capitalized terms defined in the body of this Agreement, the
      following terms will have the meaning ascribed to them below:

     

    
      	1.1  	
              “$”
                means United States Dollars.

            

    

     

    
      	1.2  	
              “1933
                Act”
                means the United States Securities Act of 1933, as amended.
                

            

    

     

    
      	1.3  	
              “1934
                Act”
                means the United States Securities Exchange Act of 1934, as amended.
                

            

    

     

    
      	1.4  	
              “Affiliate”
                means with regard to an entity (“X”),
                any entity that directly or indirectly (i) is under Control of X,
                (ii) has
                Control over X, or (iii) is under common Control with X. For this
                purpose,
                “Control”
                shall mean ownership of more than fifty percent (50%) of the equity
                or
                voting power of an entity or the right to appoint at least fifty
                percent
                (50%) of the members of the Board of Directors of such entity.
                

            

    

     

    
      	1.5  	
              “Business
                Day”
                means any day other than Saturday, Sunday or other day on which commercial
                banks in the state of Delaware generally remain
                closed.

            

    

     

    
      	1.6  	
              “Bylaws”
                means the Company’s Bylaws as in effect on the date hereof.
                

            

    

     

    
      	1.7  	
              “Certificate
                of Incorporation”
                means the Company’s Certificate of Incorporation as in effect on the date
                hereof.

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	1.8  	
              “Contingent
                Obligation”
                means, as to any Person, any direct or indirect liability, contingent
                or
                otherwise, of that Person with respect to any Indebtedness, lease,
                dividend or other obligation of another Person if the primary purpose
                or
                intent of the Person incurring such liability, or the primary effect
                thereof, is to provide assurance to the obligee of such liability
                that
                such liability will be paid or discharged, or that any agreements
                relating
                thereto will be complied with, or that the holders of such liability
                will
                be protected (in whole or in part) against loss with respect
                thereto.

            

    

     

    
      	1.9  	
              “First
                Closing”
                means the closing for the first purchase referred to in the table
                included
                in §2.2 below.

            

    

     

    
      	1.10  	
              “First
                Closing Date”
                means the date of the First
                Closing.

            

    

     

    
      	1.11  	
              “GAAP”
                means United States Generally Accepted Accounting
                Principles.

            

    

     

    
      	1.12  	
              “Indebtedness”
                of any Person means, without duplication (A) all indebtedness for
                borrowed
                money, (B) all obligations issued, undertaken or assumed as the deferred
                purchase price of property or services (other than trade payables
                entered
                into in the ordinary course of business), (C) all reimbursement or
                payment
                obligations with respect to letters of credit, surety bonds and other
                similar instruments, (D) all obligations evidenced by notes, bonds,
                debentures or similar instruments, including obligations so evidenced
                incurred in connection with the acquisition of property, assets or
                businesses, (E) all indebtedness created or arising under any conditional
                sale or other title retention agreement, or incurred as financing,
                in
                either case with respect to any property or assets acquired with
                the
                proceeds of such indebtedness (even though the rights and remedies
                of the
                seller or bank under such agreement in the event of default are limited
                to
                repossession or sale of such property), (F) all monetary obligations
                under
                any leasing or similar arrangement which, in connection with GAAP,
                consistently applied for the periods covered thereby, is classified
                as a
                capital lease, (G) all indebtedness referred to in clauses (A) through
                (F)
                above secured by (or for which the holder of such Indebtedness has
                an
                existing right, contingent or otherwise, to be secured by) any mortgage,
                lien, pledge, charge, security interest or other encumbrance upon
                or in
                any property or assets (including accounts and contract rights) owned
                by
                any Person, even though the Person which owns such assets or property
                has
                not assumed or become liable for the payment of such indebtedness,
                and (H)
                all Contingent Obligations in respect of indebtedness or obligations
                of
                others of the kinds referred to in clauses (A) through (G)
                above.

            

    

     

    
      	1.13  	
              “Investor”
                means ACCBT Corp. and any other Person designated thereby to hold
                any or
                all of the Securities.

            

    

     

    
      	1.14  	
              “Knowledge
                of the Company”
                or the “Company’s
                Knowledge”
                means the actual knowledge of the executive officers of the Company,
                after
                due inquiry.

            

    

     

    
      	1.15  	
              “Last
                Closing”
                means the closing for the last purchase referred to in the table
                included
                in §2.2 below.

            

    

     

    
      	1.16  	
              “Last
                Closing Date”
                means the date of the Last Closing.

            

    

     

    
      	1.17  	
              “Material
                Adverse Effect”
                means a material adverse effect on the business, properties, assets,
                operations, results of operations, condition (financial or otherwise)
                or
                prospects of the Company, or on the authority or ability of the Company
                to
                perform its obligations under the Transaction Documents (as defined
                below). Any adverse effect having a gross value of US$50,000 or a
                market
                price per Share of 10% less than the bid price per Share hereunder
                as of
                the closing on any trading day between 30 and 10 days prior to a
                given
                Closing shall be deemed a Material Adverse
                Effect.

            

    

     

    
      
        
        

      

      
        -2-

        
          

        

      

      
        
        

      

    

     

    
      	1.18  	
              “Person”
                means an individual, a partnership, a corporation, a limited liability
                company, an association, a joint stock company, a trust, a joint
                venture,
                an unincorporated organization, or a governmental entity (or any
                department, agency, or political subdivision
                thereof).

            

    

     

    
      	1.19  	
              “Principal
                Market”
                means the NASD’s OTC Bulletin
                Board.

            

    

     

    
      	1.20  	
              “Regulation
                D”
                means Regulation D under the 1933 Act.  

            

    

     

    
      	1.21  	
              “SEC”
                means the United States Securities and Exchange
                Commission.

            

    

     

    
      	1.22  	
              “Second
                Closing”
                means the closing for the second purchase referred to in the table
                included in §2.2 below.

            

    

     

    
      	1.23  	
              “Second
                Closing Date”
                means the date of the Second Closing.

            

    

     

    
      	1.24  	
              “Securities”
                means the Common Shares, the Warrants and the Warrant Shares,
                collectively.

            

    

     

    
      	2.  	
              BASIC
                TRANSACTION

            

    

     

    
      	2.1  	
              Purchase
                of Common Shares and Warrants.
                Subject to the satisfaction (or waiver) of the conditions set forth
                in
                Sections 6 and 7 below, and the Investor’s right to not make any further
                payments on account of the Maximum Subscription Price in accordance
                with
                Section 2.2 below, the Company shall issue and sell to the Investor,
                and
                the Investor agrees to subscribe for and purchase from the Company
                on (or,
                at the election of the Investor, before) the dates and for the
                consideration set forth below up to 27,500,000 Subscription Shares
                as
                provided below. Further, at such dates, and for no additional
                consideration, if the Investor subscribes for and purchases the relevant
                Subscription Shares, then the Company shall issue to the Investor
                Warrants
                to acquire up to 30,250,0000 additional Common Shares as provided
                below.
                For such Warrants representing the first 10,083,333 Common Shares
                issuable
                upon exercise, the Exercise Price (as defined in the Warrant) shall
                be -
                $0.20 (twenty cents) per share; for such Warrants representing the
                next
                10,083,333 Common Shares issuable upon exercise, the Exercise Price
                (as
                defined in the Warrant) shall be - $0.29 (twenty nine cents) per
                share;
                and for such Warrants representing the next 10,083,334 Common Shares
                issuable upon exercise, the Exercise Price (as defined in the Warrant)
                shall be - $0.36 (thirty six cents) per share.

            

    

     

    
      	
              Purchase
                

              Date

            	 	
              Purchase
                

              Price

            	 	
              Number
                of 

              Subscription
                Shares

            	 	
              Number
                of 

              Warrant
                Shares

            
	
              August
                30, 2007:

            	 	
              $1,250,000
                (of which $250,000 

              was
                paid on May 6, 2007)

            	 	
              6,875,000

            	 	
              7,562,500

            
	
              November
                15, 2007:

            	 	
              $750,000

            	 	
              4,125,000

            	 	
              4,537,500

            
	
              February
                15, 2008:

            	 	
              $750,000

            	 	
              4,125,000

            	 	
              4,537,500
                

            
	
              May
                15, 2008:

            	 	
              $750,000

            	 	
              4,125,000

            	 	
              4,537,500
                

            
	
              July
                30, 2008:

            	 	
              $750,000

            	 	
              4,125,000

            	 	
              4,537,500
                

            
	
              November
                15, 2008:

            	 	
              $750,000

            	 	
              4,125,000

            	 	
              4,537,500
                

            

    

     

    
      
        
        

      

      
        -3-

        
          

        

      

      
        
        

      

    

     

    
      	2.2  	
              Closings.
                Separate closings of the purchase and sale of the Subscription Shares
                and
                the Warrants (each, a “Closing”
                and together the “Closings”)
                shall occur on each of the purchase dates set forth above (each,
                a
                “Closing
                Date”)
                and shall take place at such time and place as the Company and the
                Investor shall agree. Notwithstanding the above, the Investor may
                elect to
                advance any Closing Date; provided,
                however,
                that such date will not be earlier than 7 days following such notice.
                At
                each Closing, the Company shall deliver to the Investor the number
                of
                Subscription Shares and Warrants set forth above upon the delivery to the
                Company by the Investor of a certified check or wire transfer of
                funds in
                the amount set forth opposite each purchase date above. The Subscription
                Shares deliverable to the Investor hereunder at each Closing will
                be
                evidenced by a single certificate registered in the Investor’s name
                (including, for the avoidance of doubt, a nominee as ACCBT may specify)
                and, when issued in accordance with the terms of this Agreement for
                the
                consideration expressed herein, will be duly authorized, validly
                issued,
                fully paid, nonassessable and free and clear of all preemptive or
                similar
                rights, taxes, liens and charges with respect to the issue
                thereof.

            

    

     

    
      	2.3  	
              Investor’s
                Right to Cease Payments.
                Notwithstanding the foregoing, with respect to any payment other
                than the
                payment payable by the Investor on the First Closing Date and without
                derogating from the provisions of Section 7 below, the Investor shall
                have
                the right, upon 45 days notice to the Company prior to the next scheduled
                Closing Date, to not make the next scheduled or any further payments
                on
                account of the Maximum Subscription Price (and, accordingly, the
                Company
                will not be required to issue any further Subscription Shares and
                Warrants), without incurring any liability. Upon such notice, this
                Agreement as it pertains to the transactions contemplated in connection
                with a subsequent Closing (and, at the election of the Investor,
                also in
                connection with other or all subsequent Closings) shall terminate,
                whereupon the Company shall have no claim against or recourse to
                the
                Investor and may not alter or cancel any of the Investor’s rights (other
                than the Investor’s rights to make further investments in the Company) or
                obtain any compensation from the
                Investor.

            

    

     

    
      	3.  	
              INVESTOR’S
                REPRESENTATIONS AND
                WARRANTIES

            

    

     

    The
      Investor represents and warrants to the Company that the statements contained
      in
      this Section 3‎
      are, on
      the date of this Agreement, and, as of each Closing Date, correct and complete
      (as though made then and as though each Closing Date were substituted for the
      date of this Agreement throughout this Section 3), except as set forth in Annex
      I attached hereto.

     

    
      
        
        

      

      
        -4-

        
          

        

      

      
        
        

      

    

     

    
      	3.1  	
              Organization
                of the Investor.
                The Investor is a corporation duly organized, validly existing and,
                if
                applicable, in good standing under the laws of the British Virgin
                Islands.

            

    

     

    
      	3.2  	
              Authorization;
                Enforcement; Validity.
                The
                Investor has the requisite power and authority to enter into and
                perform
                its obligations under this Agreement. The execution and delivery
                of this
                Agreement by the Investor and the consummation by the Investor of
                the
                transactions contemplated hereby have been duly authorized by the
                Investor’s Board of Directors and no further filing, consent, or
                authorization is required by the Investor, its Board of Directors
                or its
                shareholders. This Agreement has been duly executed and delivered
                by the
                Investor, and shall constitute the legal, valid and binding obligations
                of
                the Investor, enforceable against the Investor in accordance with
                its
                terms, except as such enforceability may be limited by general principles
                of equity or applicable bankruptcy, insolvency, reorganization,
                moratorium, liquidation or similar laws relating to, or affecting
                generally, the enforcement of applicable creditors’ rights and
                remedies.

            

    

     

    
      	3.3  	
              Brokers’
                Fees.
                The Investor has no liability or obligation to pay any fees or commissions
                to any broker, finder, or agent with respect to the transactions
                contemplated by this Agreement for which the Company could become
                liable
                or obligated. 

            

    

     

    
      	3.4  	
              No
                Public Sale or Distribution.
                The Investor is (i) acquiring the Subscription Shares and the Warrants
                and
                (ii) upon the exercise of the Warrants (other than pursuant to a
                Cashless
                Exercise (as defined in the Warrants)) will acquire the Warrant Shares
                issuable upon exercise of the Warrants, for its own account and not
                with a
                view towards, or for resale in connection with, the public sale or
                distribution thereof, except pursuant to sales registered or exempted
                under the 1933 Act; provided,
                however,
                that by making the representations herein, the Investor does not
                agree to
                hold any of the Securities for any minimum or other specific term
                and
                reserves the right to dispose of the Securities at any time in accordance
                with, or pursuant to, or a registration statement or an exemption
                under
                the 1933 Act. 

            

    

     

    
      	4.  	
              REPRESENTATIONS
                AND WARRANTIES OF THE
                COMPANY

            

    

     

    The
      Company (which for purposes of the representations and warranties under this
      Section 4 is deemed to include any subsidiary of the Company, unless the context
      otherwise requires) represents and warrants to the Investor that the statements
      contained in this Section 4 are correct and complete as of the date of this
      Agreement and will be correct and complete as of each Closing Date (as though
      made then and as though each Closing Date were substituted for the date of
      this
      Agreement throughout this Section 4), except as set forth in the disclosure
      schedule delivered by the Company to the Investor on the date hereof, attached
      hereto (“Disclosure
      Schedule”).
      Nothing in the Disclosure Schedule shall be deemed adequate to disclose an
      exception to a representation or warranty made herein, however, unless the
      Disclosure Schedule identifies the exception with reasonable particularity.
      The
      Disclosure Schedule will be arranged in paragraphs corresponding to the lettered
      and numbered paragraphs contained in this Section 4.

     

    
      	4.1  	
              Organization
                and Qualification.
                The Company is duly organized, validly existing and, if applicable
                under
                the laws of its place of incorporation, in good standing under such
                jurisdiction, and has the requisite power and authority to own its
                properties and to carry on its business as now being conducted. The
                Company has one subsidiary, which subsidiary is identified in Section
                4.1
                of the Disclosure Schedule.

            

    

     

    
      
        
        

      

      
        -5-

        
          

        

      

      
        
        

      

    

     

    
      	4.2  	
              Authorization;
                Enforcement; Validity.
                The Company has the requisite power and authority to enter into and
                perform its obligations under this Agreement, the Warrants, the
                Registration Rights Agreement, and each of the other agreements entered
                into by the parties hereto in connection with the transactions
                contemplated by this Agreement (collectively, the “Transaction
                Documents”)
                and to issue the Securities in accordance with the terms hereof and
                thereof. The execution and delivery of the Transaction Documents
                by the
                Company and the consummation by the Company of the transactions
                contemplated hereby and thereby, including, without limitation, the
                issuance of the Warrants, the issuance of the Warrant Shares upon
                exercise
                of the Warrants, have been duly authorized by the Company’s Board of
                Directors and no further filing, consent, or authorization is required
                by
                the Company, its Board of Directors or its shareholders. This Agreement
                and the other Transaction Documents of even date herewith have been
                duly
                executed and delivered by the Company, and shall constitute the legal,
                valid and binding obligations of the Company, enforceable against
                the
                Company in accordance with their respective terms, except as such
                enforceability may be limited by general principles of equity or
                applicable bankruptcy, insolvency, reorganization, moratorium, liquidation
                or similar laws relating to, or affecting generally, the enforcement
                of
                applicable creditors’ rights and
                remedies.

            

    

     

    
      	4.3  	
              Issuance
                of Securities.
                The issuance of the Subscription Shares and the Warrants is duly
                authorized and is free from all taxes, liens and charges with respect
                to
                the issue thereof. As of each Closing, a number of Common Shares
                shall
                have been duly authorized and reserved for issuance which equals
                at least
                110% of the maximum number of Common Shares issuable upon exercise
                of the
                Warrants. Upon issuance or exercise in accordance with the Warrants,
                and
                payment of the consideration set forth in this Agreement, the Warrants
                and
                the Warrant Shares, respectively, will be validly issued, fully paid
                and
                nonassessable and free from all preemptive or similar rights, taxes,
                liens
                and charges with respect to the issue thereof, with the holder being
                entitled to all rights accorded to a holder of Common
                Shares.

            

    

     

    
      	4.4  	
              No
                Conflicts.
                The execution, delivery and performance of the Transaction Documents
                by
                the Company and the consummation by the Company of the transactions
                contemplated hereby and thereby (including, without limitation, the
                issuance of the Warrants, and the issuance of the Warrant Shares)
                will not
                (i) result in a violation of the Certificate of Incorporation or
                the
                Bylaws or (ii) conflict with, or constitute a default (or an event
                which
                with notice or lapse of time or both would become a default) under,
                or
                result in termination, amendment, acceleration or cancellation of,
                any
                agreement, indenture or instrument to which the Company is a party,
                or
                (iii) result in a violation of any law, rule, regulation, order,
                judgment
                or decree applicable to the Company or by which any property or asset
                of
                the Company is bound or affected.

            

    

     

    
      	4.5  	
              Consents.
                The Company is not required to obtain any consent, authorization
                or order
                of, or make any filing or registration with, any court, governmental
                agency or any regulatory or self-regulatory agency or any other Person
                in
                order for it to execute, deliver or perform any of its obligations
                under
                or contemplated by the Transaction Documents, in each case in accordance
                with the terms hereof or thereof. All consents, authorizations, orders,
                filings and registrations which the Company is required to obtain
                pursuant
                to the preceding sentence shall have been obtained or effected on
                or prior
                to the First Closing Date.

            

    

     

    
      
        
        

      

      
        -6-

        
          

        

      

      
        
        

      

    

     

    
      	4.6  	
              Dilutive
                Effect.
                The Company understands and acknowledges that the number of Warrant
                Shares
                issuable upon exercise of the Warrants may increase beyond the initially
                anticipated amounts in certain circumstances. The Company further
                acknowledges that its obligation to issue the Warrant Shares upon
                exercise
                of the Warrants in accordance with this Agreement and the Warrants,
                in
                each case, is absolute and unconditional regardless of the dilutive
                effect
                that such issuance may have on the ownership interests of other
                shareholders of the Company.

            

    

     

    
      	4.7  	
              Application
                of Takeover Protections; Rights Agreement.
                The Company and its board of directors have taken all necessary action,
                if
                any, in order to render inapplicable any control share acquisition,
                business combination, poison pill (including any distribution under
                a
                rights agreement) or other similar anti-takeover provision under
                the
                Certificate of Incorporation or the laws of the jurisdiction of its
                formation which is or could become applicable to the Investor as
                a result
                of the transactions contemplated by this Agreement, including, without
                limitation, the Company’s issuance of the Securities and the Investor’s
                ownership of the Securities. The Company has not adopted a shareholder
                rights plan or similar arrangement relating to accumulations of beneficial
                ownership of Common Shares or a change in control of the
                Company.

            

    

     

    
      	4.8  	
              SEC
                Documents; Financial
                Statements

            

    

    
      	 	 

    

    
      	4.8.1  	
              During
                the two (2) years prior to the date hereof, the Company has filed
                all
                reports, schedules, forms, statements and other documents required
                to be
                filed by it with the SEC pursuant to the reporting requirements of
                the
                1934 Act with respect to such time period (all of the foregoing filed
                prior to the date hereof and all exhibits included therein and financial
                statements, notes and schedules thereto and documents incorporated
                by
                reference therein being hereinafter referred to as the “SEC
                Documents”).
                As of their respective filing dates, the SEC Documents complied in
                all
                material respects with the requirements of the 1934 Act and the rules
                and
                regulations of the SEC promulgated thereunder applicable to the SEC
                Documents, and none of the SEC Documents, at the time they were filed
                with
                the SEC, contained any untrue statement of a material fact or omitted
                to
                state a material fact required to be stated therein or necessary
                in order
                to make the statements therein, in the light of the circumstances
                under
                which they were made, not misleading. Except for registration statements
                on Form S-8, the Company has not filed any registration statements
                and any
                amendment thereto or any prospectus pursuant to Rule 424(b) under
                the 1933
                Act since January 1, 2004.

            

    

     

    
      	4.8.2  	
              As
                of their respective filing dates, the financial statements of the
                Company
                included in the SEC Documents complied in all material respects with
                applicable accounting requirements and the published rules and regulations
                of the SEC with respect thereto. Such financial statements have been
                prepared in accordance with GAAP, consistently applied, during the
                periods
                involved (except (i) as may be otherwise indicated in such financial
                statements or the notes thereto, or (ii) in the case of unaudited
                interim
                statements, to the extent they may exclude footnotes or may be condensed
                or summary statements) and fairly present in all material respects
                the
                financial position of the Company as of the dates thereof and the
                results
                of its operations and cash flows for the periods then ended (subject,
                in
                the case of unaudited statements, to normal year-end audit adjustments).
                No other information provided by or on behalf of the Company to the
                Investor in connection with the transactions contemplated hereby
                which is
                not included in the SEC Documents, contains any untrue statement
                of a
                material fact or omits to state any material fact necessary in order
                to
                make the statements therein, in the light of the circumstance under
                which
                they are or were made, not
                misleading.

            

    

     

    
      
        
        

      

      
        -7-

        
          

        

      

      
        
        

      

    

     

    
      	4.9  	
              Absence
                of Certain Changes.
                Since March 31, 2007, there has been no event which has had, or could
                reasonably be expected to result, in a Material Adverse Effect on
                the
                Company. Without derogating from the generality of the above, since
                March
                31, 2007, except in connection with the transactions contemplated
                herein,
                there has not been:

            

    

     

    
      	4.9.1  	
              any
                change in the consolidated assets, liabilities, financial condition
                or
                operating results of the Company from that reflected in the financial
                statements included in the Company’s Quarterly Report on Form 10-QSB for
                the quarter ended March 31, 2007, except for changes in the ordinary
                course of business which have not had and could not reasonably be
                expected
                to have a Material Adverse Effect, individually or in the
                aggregate;

            

    

     

    
      	4.9.2  	
              any
                declaration or payment of any dividend, or any authorization or payment
                of
                any distribution, on any of the share capital of the Company, or
                any
                redemption or repurchase of any securities of the
                Company;

            

    

     

    
      	4.9.3  	
              any
                material damage, destruction or loss, whether or not covered by insurance
                to any assets or properties of the
                Company;

            

    

     

    
      	4.9.4  	
              any
                waiver, not in the ordinary course of business, by the Company of
                a
                material right or of a material debt owed to
                it;

            

    

     

    
      	4.9.5  	
              any
                satisfaction or discharge of any lien, claim or encumbrance or payment
                of
                any obligation by the Company, except in the ordinary course of business
                and which is not material to the assets, properties, financial condition,
                operating results or business of the Company (as such business is
                presently conducted and as it is proposed to be
                conducted);

            

    

     

    
      	4.9.6  	
              any
                change or amendment to Certificate of Incorporation or the Bylaws,
                or
                material change to any material contract or arrangement by which
                the
                Company is bound or to which any of its assets or properties is
                subject;

            

    

     

    
      	4.9.7  	
              Any
                change in the number of directors of the Company or a change in the
                minimum or maximum possible seats which may constitute the board.
                

            

    

     

    
      	4.9.8  	
              any
                material labor difficulties or labor union organizing activities
                with
                respect to employees of the
                Company;

            

    

     

    
      
        
        

      

      
        -8-

        
          

        

      

      
        
        

      

    

     

    
      	4.9.9  	
              the
                loss of the services of any key employee, or material change in the
                composition or duties of the senior management of the Company; or
                

            

    

     

    
      	4.9.10  	
              any
                steps taken to seek protection pursuant to any bankruptcy law, or
                receipt
                of any notice in writing that its creditors intend to initiate involuntary
                bankruptcy proceedings.

            

    

     

    
      	4.10  	
              No
                Undisclosed Events, Liabilities, Developments or
                Circumstances.
                No material event, liability, development or circumstance has occurred
                or
                exists, or is contemplated to occur with respect to the Company,
                its
                business, properties, prospects, operations or financial condition,
                that
                would be required to be disclosed by the Company under applicable
                securities laws and which has not been publicly
                announced.

            

    

     

    
      	4.11  	
              Conduct
                of Business; Regulatory Permits.
                The Company is not in violation of any term of or in default under
                its
                Certificate of Incorporation or Bylaws. The Company is not in violation
                of
                any judgment, decree or order or any statute, ordinance, rule or
                regulation that are currently necessary or applicable to the operation
                of
                the Company as currently conducted and as proposed to be conducted,
                except
                to the extent that any such violation would not have a Material Adverse
                Effect.

            

    

     

    
      	4.12  	
              Sarbanes-Oxley
                Act; Internal Controls.
                The Company is in compliance with any and all applicable requirements
                of
                the Sarbanes-Oxley Act of 2002 that are effective and applicable
                to the
                Company as of the date hereof, and any and all applicable rules and
                regulations promulgated by the SEC thereunder that are effective
                and
                applicable to the Company as of the date hereof, except where such
                noncompliance would not have, individually or in the aggregate, a
                Material
                Adverse Effect. The Company maintains a system of internal accounting
                controls sufficient to provide reasonable assurance that (i) transactions
                are executed in accordance with management's general or specific
                authorizations, and (ii) transactions are recorded as necessary to
                permit
                preparation of financial statements in conformity with GAAP and to
                maintain asset accountability. The Company maintains and will continue
                to
                maintain a standard system of accounting established and administered
                in
                accordance with GAAP and the applicable requirements of the 1934
                Act.
                

            

    

     

    
      	4.13  	
              Transactions
                With Affiliates.
                None of the officers, directors, shareholders or employees of the
                Company
                is presently, directly or indirectly, a party to any transaction
                with the
                Company (other than for ordinary course services as employees, officers
                or
                directors), including any contract, agreement or other arrangement
                providing for the furnishing of services to or by, providing for
                rental of
                real or personal property to or from, or otherwise requiring payments
                to
                or from any such officer, director, shareholder or employee or, to
                the
                Knowledge of the Company, any corporation, partnership, trust or
                other
                entity in which any such officer, director, shareholder or employee
                has a
                substantial interest or is an officer, director, shareholder, trustee
                or
                partner.

            

    

     

    
      	4.14  	
              Equity
                Capitalization.

            

    

     

    
      	4.14.1  	
              The
                authorized share capital of the Company consists of: (i) 800,000,000
                Common Shares, of which as of the date hereof, 25,302,066 are issued
                and
                outstanding, and (ii) no shares of preferred shares. The Company
                has not
                authorized any other class or type of securities. All of such outstanding
                shares have been validly issued and are fully paid and nonassessable.
                None
                of the Company’s share capital is subject to preemptive rights or any
                other similar rights or any liens or encumbrances suffered or permitted
                by
                the Company. There are no outstanding options, warrants, scrip, rights
                to
                subscribe to, calls or commitments of any character whatsoever relating
                to, or securities or rights convertible into, or exercisable or
                exchangeable for, any share capital of the Company, or contracts,
                commitments, understandings or arrangements by which the Company
                is or may
                become bound to issue additional share capital of the Company or
                options,
                warrants, scrip, rights to subscribe to, calls or commitments of
                any
                character whatsoever relating to, or securities or rights convertible
                into, or exercisable or exchangeable for, any share capital of the
                Company. There are no outstanding debt securities, notes, credit
                agreements, credit facilities or other agreements, documents or
                instruments evidencing Indebtedness of the Company or by which the
                Company
                is or may become bound. There are no agreements or arrangements under
                which the Company is obligated to register the sale of any of its
                securities under the 1933 Act (except the Registration Rights Agreement).
                There are no outstanding securities or instruments of the Company
                which
                contain any redemption or similar provisions, and there are no contracts,
                commitments, understandings or arrangements by which the Company
                is or may
                become bound to redeem it securities. 

            

    

     

    
      
        
        

      

      
        -9-

        
          

        

      

      
        
        

      

    

     

    
      	4.14.2  	
              The
                issuance and sale of the Securities hereunder will not obligate the
                Company to issue Common Shares or other securities to any other Person
                (other than the Investor) and will not result in the adjustment of
                the
                exercise, conversion, exchange or reset price of any outstanding
                security.

            

    

     

    
      	4.14.3  	
              The
                Company has furnished to the Investor true, correct and complete
                copies of
                the Certificate of Incorporation and the Bylaws, and the terms of
                all
                securities convertible into, or exercisable or exchangeable for,
                Common
                Shares and the material rights of the holders thereof in respect
                thereto.

            

    

     

    
      	4.14.4  	
              The
                Disclosure Schedule contains a true and complete table summarizing
                the
                capitalization of the Company as of the date hereof and as of the
                First
                Closing, both on an outstanding basis and on a fully diluted as converted
                basis.

            

    

     

    
      	4.15  	
              Indebtedness.
                The Company (i) has no outstanding Indebtedness, (ii) is not a party
                to
                any contract, agreement or instrument, the violation of which, or
                default
                under which, by the other party(ies) to such contract, agreement
                or
                instrument would result in a Material Adverse Effect, (iii) is not
                in
                violation of any term of or in default under any contract, agreement
                or
                instrument relating to any Indebtedness, except where such violations
                and
                defaults would not result, individually or in the aggregate, in a
                Material
                Adverse Effect, and (iv) is not a party to any contract, agreement
                or
                instrument relating to any Indebtedness, the performance of which,
                in the
                judgment of the Company’s officers, has or is expected to have a Material
                Adverse Effect.

            

    

     

    
      	4.16  	
              Contracts

            

    

     

    Section
      ‎4.16
      of
      the Disclosure Schedule lists all material contracts to which the Company is
      a
      Party. Without derogating from the generality of the above, the following
      contracts and other agreements are deemed material:

     

    
      	4.16.1  	
              any
                agreement (or group of related agreements) for the lease of personal
                property to or from any Person providing for lease payments in excess
                of $
                10,000 per annum;

            

    

     

    
      
        
        

      

      
        -10-

        
          

        

      

      
        
        

      

    

     

    
      	4.16.2  	
              any
                agreement (or group of related agreements) for the purchase or sale
                of raw
                materials, commodities, supplies, products, or other personal property,
                or
                for the furnishing or receipt of services, the performance of which
                will
                extend over a period of more than one year, result in a loss to the
                Company, or involve consideration in excess of $
                10,000;

            

    

     

    
      	4.16.3  	
              any
                agreement concerning a partnership or joint
                venture;

            

    

     

    
      	4.16.4  	
              any
                agreement (or group of related agreements) under which it has created,
                incurred, assumed, or guaranteed any Indebtedness in excess of
                $10,000;

            

    

     

    
      	4.16.5  	
              any
                agreement concerning
                non-competition;

            

    

     

    
      	4.16.6  	
              any
                agreement with any Person that is not at arm’s length to the Company, its
                directors, officers, employees or shareholders (or any of their respective
                Affiliates);

            

    

     

    
      	4.16.7  	
              any
                profit sharing, share option, share purchase, share appreciation,
                deferred
                compensation, severance, or other plan or arrangement for the benefit
                of
                its current or former directors, officers, and
                employees;

            

    

     

    
      	4.16.8  	
              any
                collective bargaining agreement;

            

    

     

    
      	4.16.9  	
              any
                agreement for the employment of any individual on a full-time, part-time,
                consulting, or other basis providing annual compensation in excess
                of $
                40,000 or providing severance
                benefits;

            

    

     

    
      	4.16.10  	
              any
                agreement under which it has advanced or loaned any amount to any
                of its
                directors, officers, and employees;

            

    

     

    
      	4.16.11  	
              any
                agreement under which the consequences of a default or termination
                could
                have an adverse effect on the business, financial condition, operations,
                results of operations, or future prospects of the Company;
                or

            

    

     

    
      	4.16.12  	
              any
                other agreement (or group of related agreements) the performance
                of which
                involves consideration in excess of
                $40,000.

            

    

     

    
      	4.17  	
              The
                Company has delivered to the Investor a correct and complete copy
                of each
                written agreement listed in Section 4.16 of the Disclosure Schedule
                (as
                amended to date). With respect to each such agreement:
                

            

    

     

    
      	4.17.1  	
              the
                agreement is legal, valid, binding, enforceable, and in full force
                and
                effect;

            

    

     

    
      	4.17.2  	
              the
                agreement will continue to be legal, valid, binding, enforceable,
                and in
                full force and effect on identical terms following the consummation
                of the
                transactions contemplated hereby;

            

    

     

    
      	4.17.3  	
              no
                party is in breach or default, and no event has occurred which with
                notice
                or lapse of time or both would constitute a breach or default, or
                permit
                termination, modification, or acceleration, under the agreement;
                and

            

    

     

    
      
        
        

      

      
        -11-

        
          

        

      

      
        
        

      

    

     

    
      	4.17.4  	
              no
                party has repudiated any provision of the
                agreement.

            

    

     

    
      	4.18  	
              Absence
                of Litigation.
                There is no material action, suit, proceeding, inquiry or investigation
                before or by any court, public board, government agency, self-regulatory
                organization or body pending or, to the Knowledge of the Company,
                threatened in writing against or affecting the Company, the Common
                Shares,
                any of the Company’s officers or directors or the transactions
                contemplated by the Transaction Documents.

            

    

     

    
      	4.19  	
              Employee
                Relations.
                

            

    

     

    
      	4.19.1  	
              The
                Company is not a party to or bound by any collective bargaining agreements
                or other agreements with labor organizations. The Company has not
                violated
                in any material respect any laws, regulations, orders or contract
                terms,
                affecting the collective bargaining rights of employees, labor
                organizations or any laws, regulations or orders affecting employment
                discrimination, equal opportunity employment, or employees’ health,
                safety, welfare, wages and hours.

            

    

     

    
      	4.19.2  	
              (i)
                There are no labor disputes existing, or to the Company’s Knowledge,
                threatened, involving strikes, slow-downs, work stoppages, job actions,
                disputes, lockouts or any other disruptions of or by the Company’s
                employees, (ii) there has been no demand for recognition or certification
                heretofore made by any labor organization or group of employees is
                pending
                with respect to the Company, (iii) to the Company’s best Knowledge, the
                Company enjoys good labor and employee relations with its employees
                and
                labor organizations, (iv) the Company is, and at all times has been,
                in
                compliance in all material respects with all applicable laws respecting
                employment (including laws relating to classification of employees
                and
                independent contractors) and employment practices, terms and conditions
                of
                employment, wages and hours, and immigration and naturalization and
                (vi)
                the Company is not a party to, or bound by, any employment or other
                contract or agreement that contains any severance, termination pay
                or
                change of control liability or
                obligation.

            

    

     

    
      	4.20  	
              Title.
                The Company owns no real property and has good and marketable title
                to all
                personal property owned by it which is material to the business of
                the
                Company, free and clear of all liens, encumbrances and defects except
                such
                as do not materially affect the value of such property and do not
                interfere with the use made and proposed to be made of such property
                by
                the Company. Any real property and facilities and personal property
                held
                under lease by the Company are held by it under valid, subsisting
                and
                enforceable leases with such exceptions as are not material and do
                not
                interfere with the use made and proposed to be made of such property
                and
                buildings by the Company.

            

    

     

    
      	4.21  	
              Intellectual
                Property.
                There is no claim, previously asserted, pending, threatened or which,
                to
                the Knowledge of the Company, may otherwise be asserted (“Claim”)
                that would interfere with, or adversely impact upon, the Company's
                unencumbered right to use, make, sell, license, distribute, promote,
                apply, develop and make derivative works of (“Use”),
                the patents, patent rights, permits, licenses, trade secrets, trademarks
                (registered or unregistered), trademark rights, trade names, trade
                name
                rights, franchises, copyrights (registered or unregistered), inventions
                (regardless of whether patentable or not), software, confidential
                information, innovations and other intellectual property rights being
                used
                to conduct its business as now operated and as now proposed to be
                operated, or in the development, manufacture, use, distribution or
                licensing of the Company's proprietary technology, information, products,
                processes, or services (collectively, the “Intellectual
                Property Rights”).
                The Disclosure Schedule contains a list of all pending applications
                and
                registrations of any Intellectual Property Rights used by the Company.
                To
                the Knowledge of the Company, there is no reason to believe that
                the Use
                of the Intellectual Property Rights infringes, conflicts or will
                conflict
                with valid rights of any other Person. To the Knowledge of the Company,
                there is no pending or threatened claim to the effect that, and the
                Company has no reason to believe that, any such Intellectual Property
                Right is invalid or unenforceable by the Company or its licensor.
                The
                Company has no obligation known by the Company to compensate any
                Person
                for the use of any such Intellectual Property Rights, and the Company
                has
                not granted any Person any license or other rights to use in any
                manner
                any of the Intellectual Property Rights of the Company, whether requiring
                the payment of royalties or not.

            

    

     

    
      
        
        

      

      
        -12-

        
          

        

      

      
        
        

      

    

     

    
      	4.22  	
              Tax
                Status.
                The Company (i) has made or filed all income and all other tax returns,
                reports and declarations required by any taxing authority, (ii) has
                paid
                all taxes and other governmental assessments and charges that are
                material
                in amount, shown or determined to be due on such returns, reports
                and
                declarations, except those being contested in good faith and (iii)
                has set
                aside on its books provision reasonably adequate for the payment
                of all
                taxes for periods subsequent to the periods to which such returns,
                reports
                or declarations apply. There are no unpaid taxes in any material
                amount
                claimed to be due by any taxing authority, and the officers of the
                Company
                know of no basis for any such claim. All taxes and other assessments
                and
                levies that the Company is required to withhold or to collect for
                payment
                have been duly withheld and collected and paid to the proper governmental
                entity or third party when due. There are no tax liens or claims
                pending
                or, to the Company’s Knowledge, threatened against the Company or any of
                its assets or property.

            

    

     

    
      	4.23  	
              Insurance
                Coverage.
                The Company maintains in full force and effect insurance coverage
                that is
                customary for comparably situated companies for the business being
                conducted and properties owned or leased by the Company, and the
                Company
                reasonably believes such insurance coverage to be adequate against
                all
                liabilities, claims and risks against which it is customary for comparably
                situated companies to insure.

            

    

     

    
      	4.24  	
              Off
                Balance Sheet Arrangements.
                There is no transaction, arrangement, or other relationship between
                the
                Company and an unconsolidated or other off balance sheet entity that
                is
                required to be disclosed by the Company in its 1934 Act filings and
                is not
                so disclosed or that otherwise would be reasonably likely to have
                a
                Material Adverse Effect.

            

    

     

    
      	4.25  	
              Form
                S-1 Eligibility.
                The Company is eligible to register the Subscription Shares and the
                Warrant Shares for resale by the Investor using Form S-1 promulgated
                under
                the 1933 Act. 

            

    

     

    
      
        
        

      

      
        -13-

        
          

        

      

      
        
        

      

    

     

    
      	4.26  	
              Disclosures.
                The Company confirms that neither it nor any other person acting
                on its
                behalf has provided the Investor or its agents or counsel with any
                information that constitutes or might constitute material, non-public
                information. The written materials including the Company's representations
                herein and the Disclosure Schedules do not contain any untrue statement
                of
                a material fact or omit to state a material fact necessary in order
                to
                make the statements contained therein, in light of the circumstances
                under
                which they were made, not misleading.

            

    

     

    
      	4.27  	
              Board
                Composition.
                The whole Board of Directors of the Company may be comprised of six
                directors. As of the date hereof, 3 seats are occupied and 3 seats
                are
                vacant. 

            

    

     

    
      	5.  	
              COVENANTS

            

    

     

    
      	5.1  	
              Pre-Closing
                Covenants.
                The following shall apply between the date of execution of this Agreement
                and the First Closing:

            

    

     

    
      	5.1.1  	
              The
                Company will give any notices to third parties, and will use its
                best
                efforts to obtain any third party consents, that the Investor may
                reasonably request or is required or advisable in connection with
                the
                matters referred to in Section 4.5 above. Each of the parties hereto
                will
                give any notices to, make any filings with, and use its reasonable
                best
                efforts to obtain any authorizations, consents, and approvals of
                governments and governmental agencies as may be required to execute
                and
                deliver the transactions contemplated by the Transaction
                Documents;

            

    

     

    
      	5.1.2  	
              The
                Company shall not engage in any practice, take any action, or enter
                into
                any transaction outside the ordinary course of business. Without
                limiting
                the generality of the foregoing, the Company shall not engage in
                any
                practice, take any action, or enter into any transaction of the sort
                described in Section 4.9 above;

            

    

     

    
      	5.1.3  	
              The
                Company will permit representatives of the Investor to have full
                access to
                all premises, properties, personnel, books, records, contracts, and
                documents of or pertaining to the Company during normal business
                hours
                upon prior notice to the Company, provided
                that
                the Company may withhold material non-public information of the Company
                if
                required to protect confidentiality of such information, except if
                the
                Investor agrees to maintain confidentiality of such information upon
                reasonable terms and conditions, which the Company shall propose;
                and;

            

    

     

    
      	5.1.4  	
              The
                Company shall keep its business and properties substantially intact,
                including its present operations, physical facilities, working conditions
                as well as its relations with financial institutions, suppliers,
                prospective customers, and employees. The business of the Company
                shall
                not be conducted in violation of any law, ordinance or regulation
                of any
                governmental entity.

            

    

     

    
      	5.2  	
              Adjustment
                of the Number of Shares and Price Per Share.
                In the event that at any time prior to the First Closing Date, the
                Company
                issues more Common Shares or other securities convertible into,
                exercisable or exchangeable for Common Shares, then the number of
                Subscription Shares and the price per share (but not the payment
                amounts
                or Maximum Subscription Price) will be adjusted to ensure that the
                Investor shall have the right to acquire up to 52.35% of the equity
                of the
                Company on a fully diluted as converted basis (assuming the Investor
                purchases all of the Subscription Shares and exercises in full all
                of the
                Warrants) and 50.02% of the issued and outstanding shares of the
                Company
                assuming the Investor invests the Maximum Subscription Price. In
                case the
                Investor invests less then the Maximum Subscription Price, the calculation
                will be “pro-rata” to the actual investment made by the
                Investor.

            

    

     

    
      
        
        

      

      
        -14-

        
          

        

      

      
        
        

      

    

     

    
      	5.3  	
              Pre-emptive
                Right

            

    

     

    
      	5.3.1  	
              For
                so long as the Investor holds (taking into account, for the avoidance
                of
                doubt, a designee of ACCBT) at least 5% of the Company’s issued and
                outstanding Common Shares, if any additional shares or other securities
                of
                the Company, or options or rights to purchase shares of the Company
                or
                other securities directly or indirectly convertible into or exercisable
                for shares of the Company (including for greater certainty, shares
                of any
                newly created class or series) (collectively referred to in this
                Section
                as “Additional
                Securities”),
                are to be issued, the Company will offer the Investor to purchase
                its Pro
                Rata Share (as defined below) of such Additional Securities by notice
                given to it of the Company’s intention to issue Additional Securities, the
                aggregate and per Additional Security payable, and the number of
                such
                Additional Securities to be so issued. The Investor’s “Pro
                Rata Share”
                of
                the Additional Securities shall be equal to the total number of Additional
                Securities so offered, multiplied by the quotient of X/Y, where X
                is equal
                to the number of Common Shares beneficially owned on a fully-diluted
                as
                converted basis by the Investor (including, for the avoidance of
                doubt, a
                designee of ACCBT), and Y is equal to aggregate number of outstanding
                Common Shares beneficially owned on a fully-diluted as converted
                basis by
                all of the shareholders of the Company, all as at the date notice
                is given
                of such offer. The Investor will have 30 days from the date such
                notice is
                given to give a notice to the Company (the “Notice
                of Subscription”)
                of its intention to purchase all or any of the Additional Securities
                to
                which it is entitled and will indicate in such notice the maximum
                number
                of Additional Securities that it is willing to purchase (which number
                may
                be greater than or less than its Pro Rata Share). Should the Investor
                wish
                to
                subscribe for Additional Securities in excess of its Pro Rata Share,
                it
                shall, in the Notice of Subscription, specify the number or dollar
                amount,
                as the case may be, of Additional Securities in excess of its Pro
                Rata
                Share that the Investor wishes to purchase.
                Any Additional
                Securities remaining unsubscribed for following such 30 days shall
                be used
                to satisfy the subscription of the Investor for Additional Securities
                in
                excess of its Pro Rata Shares but the Investor shall not be bound
                to take
                any Additional Securities in excess of the maximum amount it requested
                to
                purchase in its Notice of Subscription. The
                transaction of purchase and sale by the Company to the Investor pursuant
                to this Section 5.3 will be completed on the date specified by the
                board of directors of the Company, but not later than 30 days from
                the
                Notice of Subscription (as such date may be delayed by the duration
                necessary to obtain any regulatory approvals or consents). Any Additional
                Securities not taken up by the Investor may be issued within 90 days
                of
                such Additional Securities having been first offered to the Investor,
                at
                not less than the price and on terms no more favorable than the terms
                originally offered to the Investor, to such Persons as the board
                of
                directors of the Company determines. 

            

    

     

    
      
        
        

      

      
        -15-

        
          

        

      

      
        
        

      

    

     

    
      	5.3.2  	
              The
                Company may issue Additional Securities without complying with the
                provisions of Section 5.3.1 above if such Additional Securities are
                permitted to be issued under sub-clauses (i) and (iii) of Section
                5.7.2
                below.

            

    

     

    
      	5.4  	
              Board
                Composition.
                The Company shall cause the following to take place timely:
                

            

    

     

    
      	5.4.1  	
              Immediately
                following the First Closing and thereafter (subject to Investor’s right to
                appoint 50.1% of the Board pursuant to Section 5.4.2 below), the
                Investor
                will be entitled to appoint 40% of the members of the Board of Directors
                of the Company and its subsidiary (fractions to be rounded up to
                the
                nearest whole number (and the same proportion shall apply to any
                committee), unless the rules of the SEC or any applicable securities
                exchange prohibit such. In order to effect this provision, then on
                or
                before the First Closing, the Company will have caused the election
                two
                nominees of the Investor to the Board of Directors of the Company,
                which
                shall number no more than 5, subject only to such Closing.
                

            

    

     

    
      	5.4.2  	
              Upon
                payment of the first $2 million of the Maximum Subscription Price,
                the
                Investor shall be entitled to appoint 50.1% of the Board of Directors
                of
                the Company and its subsidiary (fractions to be rounded up to the
                nearest
                whole number) (and the same proportion shall apply to any committee),
                unless the rules of the SEC or any applicable securities exchange
                prohibit
                such. In order to effect this provision, on or before the Second
                Closing,
                the Company will have caused the election 3 nominees of the Investor
                to
                the Board of Directors of the Company, which shall number no more
                than 5,
                subject only to such Closing.. 

            

    

     

    
      	5.4.3  	
              Following
                the First Closing Date, if the Investor elects to exercise its right
                to
                not make further payments toward the Maximum Subscription Price to
                the
                Company as set forth in Section 2.3 above and at when so ceasing
                it shall
                have paid less than US$4 million of the Maximum Subscription Price,
                then
                the Investor will be entitled to appoint only 40% of the members
                of the
                Board of Directors of the Company and its subsidiary (fractions to
                be
                rounded up to the nearest whole number) (and the same proportion
                shall
                apply to any committee).

            

    

     

    
      	5.4.4  	
              The
                Investor's right to designate members of the Board of Directors shall
                automatically terminate at such time as the Investor holds less than
                5% of
                the issued and outstanding share capital of the Company. In addition,
                the
                Investor's rights under this §5.4 are subject to the rules and regulations
                of any applicable securities
                exchange.

            

    

     

    
      
        
        

      

      
        -16-

        
          

        

      

      
        
        

      

    

     

    
      	5.5  	
              Cancellation
                of Certain Issued Warrant and Debenture.
                Upon the First Closing, the Investor will surrender to the Company
                the
                form of promissory note and warrants issued to the Investor on May
                6,
                2007, whereupon such promissory note and warrants will be deemed
                null and
                void. The parties hereto agree that the amount of $250,000 paid by
                the
                Investor in connection with the aforementioned issuance will be considered
                a payment made on the First Closing Date towards the payment due
                on such
                date (i.e., $1.25 million).

            

    

     

    
      	5.6  	
              Security
                Holders Agreement.
                (i) The Investor, and (ii) certain security holders of the Company
                holding
                at least 31% of the issued and outstanding shares of the Company
                as at the
                date hereof shall have entered into a security holders agreement
                with the
                Investor in the form attached hereto as Exhibit
                C.

            

    

     

    
      	5.7  	
              Protective
                Provisions.
                For so long as the Investor holds (taking into account, for the avoidance
                of doubt, a designee of ACCBT) at least 5% of the issued and outstanding
                share capital of the Company, no obligation of the Company (which,
                for
                purposes of this Section is deemed to include any subsidiary of the
                Company) will be entered into, no decision will be made, and no action
                will be taken by or with respect to the Company, either directly
                or
                indirectly (including by merger, consolidation or reclassification,
                or
                through the making of any shareholder proposal by any of its shareholder),
                with respect to the following matters without the written consent
                of the
                Investor: 

            

    

     

    
      	5.7.1  	
              any
                change in the Certificate of Incorporation or the Bylaws, or alteration
                of
                the capital structure of the Company through any reclassification
                or
                consolidation;

            

    

     

    
      	5.7.2  	
              the
                allotment or issuance of any shares or other securities (including
                convertible debt) of the Company (or the entering into of any agreement
                or
                the making of any offer or the granting of any right capable of becoming
                an agreement to allot or issue any shares or other securities of
                the
                Company), except for: (i) shares issuable pursuant to (A) the Warrants,
                this Agreement and outstanding share options, convertible debt or
                warrants
                existing as of the date hereof, (B) up to 2,180,000 shares issuable
                to
                Company’s service providers under existing arrangements, and Common Shares
                under the Company’s equity incentive plans (where applicable), and (C)
                shares issuable as an introduction fee for the transaction contemplated
                hereby acceptable to the Investor, at its sole discretion; (ii) where
                the
                Investor has given notice of its declination, or otherwise fails,
                to make
                further payments toward the Maximum Subscription Price; and (iii)
                where
                prior to the First Closing the Company accepts any offer for investment
                in
                the Company of up to $500,000, in the same terms of the investments
                made
                by Meir Rosenbaum as of March 14, 2007; 

            

    

     

    
      
        
        

      

      
        -17-

        
          

        

      

      
        
        

      

    

     

    
      	5.7.3  	
              the
                redemption, repurchase or other acquisition by the Company of any
                of its
                shares (or the payment into or setting aside of a fund for such
                purpose);

            

    

     

    
      	5.7.4  	
              the
                declaration or payment of any dividend or the making of any distributions
                to any holders of any shares in the capital of the
                Company;

            

    

     

    
      	5.7.5  	
              any
                dealings with, or the making of any payments to, any Person that
                is not at
                arm’s length to the Company, its directors, officers, employees or
                shareholders (or any of their respective Affiliates), except for
                those
                outstanding obligations existing as of the date
                hereof;

            

    

     

    
      	5.7.6  	
              the
                sale, lease, exchange or other disposition granting of a security
                interest
                in, or exclusive license of, any material part of or all or substantially
                all of the property or assets (including intellectual property) of
                the
                Company or the incurrence of any Indebtedness or capital expenditures
                greater than $25,000 (except in the ordinary course of business or
                for a
                debt investment in the Company up to $500,000 prior to the First
                Closing
                Date);

            

    

     

    
      	5.7.7  	
              the
                taking of any steps to voluntarily liquidate, dissolve, wind-up or
                otherwise terminate the corporate existence of the
                Company;

            

    

     

    
      	5.7.8  	
              the
                creation, acquisition or disposition of any subsidiary, the purchase
                or
                acquisition of any partnership interest or securities issued by,
                or other
                equity or ownership interest in, any other entity, participation
                in any
                joint venture or strategic
                alliance;

            

    

     

    
      	5.7.9  	
              any
                material change to the direction of the business of the Company or
                the
                related business plan as described in the SEC
                Documents;

            

    

     

    
      	5.7.10  	
              engage
                in any share sale or exchange, merger, consolidation, amalgamation,
                arrangement, asset acquisition or any other similar transaction the
                effect
                of which is to place control of the business of the Company in the
                hands
                of an arm’s length third party;

            

    

     

    
      	5.7.11  	
              any
                acquisition of at least the majority of shares or all, or substantially
                all, of the assets of any other
                Person;

            

    

     

    
      	5.7.12  	
              pay
                any compensation to any officer, director or employee involving a
                cash or
                cash equivalent commitment of more than US$60,000 per annum (not
                taking
                into account any share-based awards pursuant to a board approved
                plan or
                existing arrangements); or

            

    

     

    
      	5.7.13  	
              any
                commitment or agreement to do any of the
                foregoing.

            

    

     

    
      	5.8  	
              Best
                Efforts.
                Each party hereto shall use its best efforts timely to satisfy each
                of the
                applicable conditions to be satisfied by it as provided in Sections
                6 and
                7 of this Agreement.

            

    

     

    
      
        
        

      

      
        -18-

        
          

        

      

      
        
        

      

    

     

    
      	5.9  	
              Form
                D and Blue Sky.
                The Company agrees to file a Form D with respect to the Securities
                as
                required under Regulation D and to provide a copy thereof to the
                Investor
                promptly after such filing. The Company shall, on or before the First
                Closing Date, take such action as the Company shall reasonably determine
                is necessary in order to obtain an exemption for or to qualify the
                Securities for sale to the Investor at the First Closing pursuant
                to this
                Agreement under applicable securities or “Blue Sky” laws of the states of
                the United States (or to obtain an exemption from such qualification),
                and
                shall provide evidence of any such action so taken to the Investor
                on or
                prior to the First Closing Date. The Company shall make all filings
                and
                reports relating to the offer and sale of the Securities required
                under
                applicable securities or “Blue Sky” laws of the states of the United
                States following the First Closing
                Date.

            

    

     

    
      	5.10  	
              Reporting
                Status.
                Until the date on which the Investor shall have sold all the Subscription
                Shares and the Warrant Shares and none of the Warrants is outstanding,
                the
                Company shall file all reports required to be filed with the SEC
                pursuant
                to the 1934 Act, and the Company shall not terminate its status as
                an
                issuer required to file reports under the 1934 Act even if the 1934
                Act or
                the rules and regulations thereunder would otherwise permit such
                termination.

            

    

     

    
      	5.11  	
              Listing.
                The Company shall promptly secure the listing of all of the Registrable
                Securities upon each national securities exchange and automated quotation
                system, if any, upon which the Common Shares are then listed and
                shall
                maintain such listing of all Registrable Securities from time to
                time
                issuable under the terms of the Transaction Documents. The Company
                shall
                maintain the Common Shares’ authorization for quotation on the Principal
                Market. Neither the Company nor any of its Subsidiaries shall take
                any
                action which would be reasonably expected to result in the delisting
                or
                suspension of the Common Shares on the Principal Market. The Company
                shall
                pay all fees and expenses in connection with satisfying its obligations
                under this Section.

            

    

     

    
      	5.12  	
              Reservation
                of Common Shares.
                Subject to Section 2.3 above, the Company shall at all times reserve
                and
                keep available out of its authorized but unissued Common Shares,
                solely
                for the purpose of providing for the issuance of the Subscription
                Shares
                and the exercise of the Warrants, such number of Common Shares as
                shall
                from time to time equal the number of all possible Subscription Shares
                not
                yet issued and Warrant Shares issuable upon the due exercise of the
                Warrants in accordance with their respective
                terms.

            

    

     

    
      	5.13  	
              Notice
                of Developments.
                The Company will give prompt written notice to the Investor of any
                material adverse development causing a breach of any of the
                representations and warranties in Section 4 above. No disclosure
                pursuant
                to this Section 5.13, however, shall be deemed to amend or supplement
                the
                Disclosure Schedule or to prevent or cure any misrepresentation,
                breach of
                warranty, or breach of covenant. 

            

    

     

    
      	5.14  	
              No
                Conflicting Agreements.
                The Company will not take any action, enter into any agreement or
                make any
                commitment that would conflict or interfere in any material respect
                with
                the Company’s obligations to the Investor under the Transaction
                Documents.

            

    

     

    
      	5.15  	
              Compliance
                with Laws.
                The Company will comply in all material respects with all applicable
                laws,
                rules, regulations, orders and decrees of all governmental
                authorities.

            

    

     

    
      
        
        

      

      
        -19-

        
          

        

      

      
        
        

      

    

     

    
      	5.16  	
              Use
                of Proceeds.
                The net proceeds of the sale of the Subscription Shares and Warrants
                hereunder shall be used by the Company for working capital and general
                corporate purposes.

            

    

     

    
      	5.17  	
              Exclusivity.
                Between the date of execution of this Agreement and the First Closing,
                the
                Company shall not:

            

    

     

    
      	5.17.1  	
              solicit,
                initiate, or encourage the submission of any proposal or offer from
                any
                Person relating to the acquisition of any Securities or other voting
                securities, or any substantial portion of the assets, of the Company
                (including any acquisition structured as a merger, consolidation,
                or share
                exchange); or 

            

    

     

    
      	5.17.2  	
              participate
                in any discussions or negotiations regarding, furnish any information
                with
                respect to, assist or participate in, or facilitate in any other
                manner
                any effort or attempt by any Person to do or seek any of the foregoing.
                The Company will notify the Investor immediately if any Person makes
                any
                proposal, offer, inquiry, or contact with respect to any of the
                foregoing.

            

    

     

    
      	6.  	
              CONDITIONS
                TO THE COMPANY’S
                OBLIGATION TO ISSUE

            

    

     

    The
      obligation of the Company hereunder to issue and sell the applicable
      Subscription Shares to the Investor at each Closing is subject to the
      satisfaction, at or before the relevant Closing Date, of each of the following
      conditions (if such remain relevant in a subsequent Closing), provided that
      these conditions are for the Company’s sole benefit and may be waived by the
      Company at any time in its sole discretion by providing the Investor with prior
      written notice thereof:

     

    
      	6.1  	
              The
                representations and warranties of the Investor shall be true and
                correct
                in all material respects as of the date when made and as of the relevant
                Closing Date as though made at that time (except for representations
                and
                warranties that speak as of a specific date), and the Investor shall
                have
                performed, satisfied and complied in all material respects with the
                covenants, agreements and conditions required by this Agreement to
                be
                performed, satisfied or complied with by the Investor at or prior
                to the
                relevant Closing Date;

            

    

     

    
      	6.2  	
              The
                Investor shall have executed and delivered to the Company each of
                the
                Transaction Documents to be delivered by the Investor hereunder together
                with the applicable proceeds of the investment;
                and

            

    

     

    
      	6.3  	
              All
                of the terms, covenants and conditions
                of
                this Agreement to be performed and/or complied with by the Investor
                at or
                prior to the relevant Closing Date shall have been performed or complied
                with. 

            

    

     

    
      	7.  	
              CONDITIONS
                TO THE
                INVESTOR’S OBLIGATION TO SUBCSCRIBE

            

    

     

    Without
      derogating from the provisions of Section 2.3 above, the obligation of the
      Investor to purchase the relevant Subscription Shares at each Closing is subject
      to the satisfaction, at or before the relevant Closing Date, of each and all
      of
      the following conditions (if such remain relevant in a subsequent Closing),
      provided that these conditions are for the Investor’s sole benefit and may be
      waived by the Investor at any time in its sole discretion by providing the
      Company with prior written notice thereof:

     

    
      	7.1  	
              The
                Company shall have executed and delivered to the Investor: (A) each
                of the
                Transaction Documents, and (B) the Warrants;

            

    

     

    
      
        
        

      

      
        -20-

        
          

        

      

      
        
        

      

    

     

    
      	7.2  	
              (i)
                The Investor and (ii) certain security holders of the Company,
                representing at least 31% of the issued and outstanding shares of
                the
                Company as at the date hereof, shall have entered into the security
                holders agreement set forth in Exhibit C.

            

    

     

    
      	7.3  	
              The
                Company shall have taken such actions under the Company's Certificate
                of
                Incorporation and Bylaws and rights plan as may be necessary in the
                reasonable opinion of the Investor’s counsel to permit the purchase of the
                Subscription Shares and the Warrant Shares and to establish the rights
                of
                the Investor as contemplated under the Transaction Documents.
                

            

    

     

    
      	7.4  	
              The
                representations and warranties of the Company shall be true and correct
                as
                of the date when made and as of each Closing Date as though made
                at that
                time (except for representations and warranties that speak as of
                a
                specific date), the Company shall have performed, satisfied and complied
                in all respects with the covenants, agreements and conditions required
                by
                the Transaction Documents to be performed, satisfied or complied
                with by
                the Company at or prior to each Closing Date,
                and no event has occurred which has had, or could reasonably be expected
                to result, in a Material Adverse Effect on the
                Company;

            

    

     

    
      	7.5  	
              The
                Company shall have obtained all governmental, regulatory or third
                party
                consents and approvals, if any, necessary for the sale and issuance
                of the
                Securities;

            

    

     

    
      	7.6  	
              No
                action, suit, or proceeding shall be pending or threatened before
                any
                court or quasi-judicial or administrative agency or before any arbitrator
                wherein an unfavorable injunction, judgment, order, decree, ruling,
                or
                charge would:

            

    

     

    
      	7.6.1  	
              prevent
                consummation of any of the transactions contemplated hereby and by
                the
                other Transaction Documents, 

            

    

     

    
      	7.6.2  	
              cause
                any of the transactions contemplated hereby and by the other Transaction
                Documents to be rescinded following consummation,
                or

            

    

     

    
      	7.6.3  	
              affect
                adversely the right of the Investor to own the Subscription Shares
                and/or
                the Warrant Shares.

            

    

    
      	 	 

    

    
      	7.7  	
              The
                Investor shall have received a certificate, executed by the Chief
                Executive Officer (or principal executive officer) of the Company,
                dated
                as of each Closing Date, to the effect that each of the applicable
                conditions specified in Sections 7.2 through 7.6 above is satisfied
                in all
                material respects;

            

    

     

    
      	7.8  	
              The
                Company shall have delivered to the Investor a certificate, executed
                by
                the Chief Executive Officer (or principal executive officer) of the
                Company and dated as of the First Closing Date, attaching and confirm
                the
                due passage and in-effect status of (i) resolutions adopted by the
                Company’s Board of Directors to approve the transactions contemplated by
                this Agreement and the other Transaction Documents, (ii) the Certificate
                of Incorporation and (iii) the Bylaws, each as in effect at the First
                Closing;

            

    

     

    
      	7.9  	
              By
                the First Closing the relevant parties shall have entered into the
                Registration Right Agreement;

            

    

     

    
      
        
        

      

      
        -21-

        
          

        

      

      
        
        

      

    

     

    
      	7.10  	
              The
                Company and Ramot at Tel Aviv University Ltd. shall have (A) amended
                (i)
                the Research and License Agreement between them dated March 30, 2006,
                and
                (ii) the related Warrants, and (B) Ramot shall have waived all breaches
                of
                the Company under such Agreement and/or Warrants until the First
                Closing
                Date, all of the foregoing to the satisfaction of the
                Investor;

            

    

     

    
      	7.11  	
              The
                Company's subsidiary shall have obtained written approval of the
                transactions contemplated hereby from Kiryat HaMada Ve'Hatechnologiya
                and
                others, the lessors of the Company's subsidiary's offices in Petach
                Tikva,
                to the satisfaction of Investor. 

            

    

     

    
      	7.12  	
              The
                Company shall have obtained Directors and Officers liability insurance
                to
                the Investor's satisfaction. 

            

    

     

    
      	7.13  	
              The
                Company shall have delivered to the Investor such other customary
                documents relating to the transactions contemplated by this Agreement
                as
                the Investor or its counsel may reasonably request.
                All actions to be taken by the Company in connection with consummation
                of
                the transactions contemplated hereby and all certificates, instruments,
                and other documents required to effect the transactions contemplated
                hereby will be reasonably satisfactory in form and substance to the
                Investor.

            

    

     

    
      	8.  	
              INDEMNIFICATION 

            

    

     

    
      	8.1  	
              Company’s
                Obligation to Indemnify.
                The Company shall defend, protect, indemnify and hold harmless the
                Investor (including, for the avoidance of doubt, each other holder
                of the
                Securities) (collectively, the “Indemnitees”)
                from and against any and all actions, causes of action, suits, claims,
                losses, costs, penalties, fees, liabilities and damages, and expenses
                (“Claim”)
                in connection therewith (irrespective of whether any such Indemnitee
                is a
                party to the action for which indemnification hereunder is sought),
                and
                including reasonable attorneys’ fees and disbursements and the reasonable
                cost of enforcement of this indemnity (“Indemnified
                Liabilities”),
                incurred by any Indemnitee as a result of, or arising out of, or
                relating
                to (a) any misrepresentation or breach of any representation or warranty
                made by the Company in the Transaction Documents, or any other
                certificate, instrument or document contemplated hereby or thereby,
                or (b)
                any breach of any covenant, agreement or obligation of the Company
                contained in the Transaction Documents or any other certificate,
                instrument or document contemplated hereby or
                thereby.

            

    

     

    
      	8.2  	
              Indemnification
                Procedure.
                Promptly after receipt by an Indemnitee under this Section 8 of notice
                of
                the commencement of any action or proceeding (including any governmental
                action or proceeding) involving a Claim, such Indemnitee shall, if
                a Claim
                in respect thereof is to be made against the Company under this Section
                8,
                deliver to the Company a written notice of the commencement thereof
                including the factual basis for the Claim (if known) and the amount,
                and
                the Company shall have the right to participate in, and, to the extent
                the
                Company so desires, to assume control of the defense thereof with
                counsel
                mutually satisfactory to the Company and the Indemnitee. The Indemnitee
                shall cooperate fully with the Company in connection with any negotiation
                or defense of any such action or proceeding by the Company and shall
                furnish to the Company all information reasonably available to the
                Indemnitee which relates to such action or proceeding. The Company
                shall
                keep the Indemnitee reasonably apprised at all times as to the status
                of
                the defense or any settlement negotiations with respect thereto.
                The
                Company shall not be liable for any settlement of any action, claim
                or
                proceeding effected without its prior written consent (excluding
                where the
                Company has not elected to assume control of the defense), provided,
                however,
                that the Company shall not unreasonably withhold, delay or condition
                its
                consent. The Company shall not, without the prior written consent
                of the
                Indemnitee, consent to entry of any judgment or enter into any settlement
                or other compromise which does not include as an unconditional term
                thereof the giving by the claimant or plaintiff to such Indemnitee
                of a
                release from all liability in respect to such action, proceeding
                or
                litigation, and such settlement shall not include any admission as
                to
                fault on the part of the Indemnitee. Following indemnification as
                provided
                for hereunder, the Company shall be subrogated to all rights of the
                Indemnitee with respect to all insurance proceeds, third parties,
                firms or
                corporations relating to the matter for which indemnification has
                been
                made. The failure by an Indemnitee to deliver written notice to the
                Company within a reasonable time of the commencement of any such
                action
                shall not relieve the Company of any liability to the Indemnitee
                under
                this Section 8 except to the extent that the Company is prejudiced
                in its
                ability to defend such action, in which event the liability of the
                Company
                to such Indemnitee shall be reduced by the amount of any losses incurred
                by the Company resulting from the Indemnitee’s failure to give such notice
                on a timely basis.

            

    

     

    
      
        
        

      

      
        -22-

        
          

        

      

      
        
        

      

    

     

    
      	9.  	
              TERMINATION

            

    

     

    In
      the
      event that any of the Closings shall not have occurred on or before the Closing
      Date designated for such Closing as set forth in Section 2.1 above due to the
      Company’s or the Investor’s failure to satisfy the conditions set forth in
      Sections 6 and 7 above (and the non-breaching party’s failure to waive such
      unsatisfied condition(s)), the non-breaching party shall have the option to
      terminate this Agreement at the close of business on such date as it pertains
      to
      the transactions contemplated in connection with the relevant Closing (and,
      at
      the non-breaching party’s election also in connection with all subsequent
      Closings) without liability of a party to the other party. Nothing in this
      Section 9 shall be deemed to release a party from any liability for any breach
      by such party of the applicable terms and provisions of this Agreement or the
      other Transaction Documents or to impair the right of a party to compel specific
      performance by the other party of its obligations under this Agreement or the
      other Transaction Documents.

     

     

    
      	10.  	
              Miscellaneous

            

    

     

    
      	10.1  	
              Governing
                Law; Consent to Jurisdiction.
                This Agreement shall be governed by, and construed in accordance
                with, the
                internal laws of the State of Israel without regard to the choice
                of law
                principles thereof. Each of the parties hereto irrevocably submits
                to the
                jurisdiction of the courts located in Israel (but not elsewhere)
                for the
                purpose of any suit, action, proceeding or judgment relating to or
                arising
                out of this Agreement and the transactions contemplated hereby. Service
                of
                process in connection with any such suit, action or proceeding may
                be
                served on each party hereto anywhere in the world by the same methods
                as
                are specified for the giving of notices under this Agreement. Each
                of the
                parties hereto irrevocably consents to the jurisdiction of any such
                court
                in any such suit, action or proceeding and to the laying of venue
                in such
                court. Each party hereto irrevocably waives any objection to the
                laying of
                venue of any such suit, action or proceeding brought in such courts
                and
                irrevocably waives any claim that any such suit, action or proceeding
                brought in any such court has been brought in an inconvenient
                forum.

            

    

     

    
      
        
        

      

      
        -23-

        
          

        

      

      
        
        

      

    

     

    
      	10.2  	
              Counterparts.
                This Agreement may be executed in two or more identical counterparts,
                all
                of which shall be considered one and the same agreement and shall
                become
                effective when counterparts have been signed by each party and delivered
                to the other party; provided that a facsimile signature shall be
                considered due execution and shall be binding upon the signatory
                thereto
                with the same force and effect as if the signature were an original,
                not a
                facsimile signature.

            

    

     

    
      	10.3  	
              Construction 

            

    

     

    
      	10.3.1  	
              The
                recitals hereto constitute an integral part hereof.
                

            

    

     

    
      	10.3.2  	
              The
                exhibits to this Agreement are incorporated herein by reference and
                made a
                part hereof.

            

    

     

    
      	10.3.3  	
              The
                headings of this Agreement are for convenience of reference and shall
                not
                form part of, or affect the interpretation of, this
                Agreement.

            

    

     

    
      	10.3.4  	
              The
                word including shall mean including but not limited
                to.

            

    

     

    
      	10.3.5  	
              This
                Agreement shall be construed as if drafted jointly by the parties
                hereto
                and no presumption or burden of proof shall arise favoring or disfavoring
                any party by virtue of the authorship of any of the provisions of
                this
                Agreement.

            

    

     

    
      	10.4  	
              Severability.
                If any provision of this Agreement shall be invalid or unenforceable
                in
                any jurisdiction, such invalidity or unenforceability shall not affect
                the
                validity or enforceability of the remainder of this Agreement in
                that
                jurisdiction or the validity or enforceability of any provision of
                this
                Agreement in any other
                jurisdiction.

            

    

     

    
      	10.5  	
              Entire
                Agreement; Amendments.
                This Agreement and the other Transaction Documents supersede all
                other
                prior oral or written agreements between the Investor, the Company,
                their
                Affiliates and Persons acting on their behalf with respect to the
                matters
                discussed herein and therein, and this Agreement, the other Transaction
                Documents and the instruments referenced herein contain the entire
                understanding of the parties with respect to the matters covered
                herein
                and therein. No provision of this Agreement may be amended other
                than by
                an instrument in writing signed by the Company and the Investor and
                any
                amendment to this Agreement made in conformity with the provisions
                of this
                Section 10.5 shall be binding on the Investor and holders of Securities,
                as applicable. No provision hereof may be waived other than by an
                instrument in writing signed by the party against whom enforcement
                is
                sought.

            

    

     

    
      	10.6  	
              Notices.
                Any notices, consents, waivers or other communications required or
                permitted to be given under the terms of this Agreement must be in
                writing
                and will be deemed to have been delivered: (i) upon receipt, when
                delivered personally; (ii) upon receipt, and when sent by facsimile
                (provided confirmation of transmission is mechanically or electronically
                generated and kept on file by the sending party); or (iii) one Business
                Day after deposit with an overnight courier service, in each case
                properly
                addressed to the party to receive the same. The addresses and facsimile
                numbers for such communications shall
                be:

            

    

     

    If
      to Company:

    

    Brainstorm
      Cell Therapeutic Inc.

    12
      Basel
      St. Petach Tikva

    Tel:
      +972-3-9236384

    Fax:
      +972-3-9236385

    Atten.:
      Yoram Drucker

    

    
      
        
        

      

      
        -24-

        
          

        

      

      
        
        

      

    

     

    With
      a Copy to:

    

    BRL
      Law
      Group LLC

    31
      St.
      James Avenue, Suite 850

    Boston,
      MA 02116

    Attention:
      Thomas B. Rosedale

    

    If
      to Investor:

    

    ACCBT
      Corp.

    Morgan
      & Morgan Building

    Pasea
      Estate, Road Town, Tortola

    BVI

    Tel:

    Fax:

    Atten.:
      Mr. Chaim Lebovitch

    

    With
      a Copy to:

    

    Caspi
      & Co.

    33
      Yavetz
      St

    65258
      Tel
      Aviv, Israel

    Tel:
      +972-3-7961000

    Fax:
      +972-3-7961001

    Atten.:
      Norman Menachem Feder

     

    or
      to
      such other address and/or facsimile number and/or to the attention of such
      other
      Person as the recipient party has specified by written notice given to the
      other
      party five (5) Business Days prior to the effectiveness of such change. Written
      confirmation of receipt (A) given by the recipient of such notice, consent,
      waiver or other communication, (B) mechanically or electronically generated
      by
      the sender’s facsimile machine containing the time, date, recipient facsimile
      number and an image of the first page of such transmission or (C) provided
      by an
      overnight courier service shall be rebuttable evidence of personal service,
      receipt by facsimile or receipt from an overnight courier service in accordance
      with clause (i), (ii) or (iii) above, respectively.

     

    
      	10.7  	
              Successors
                and Assigns.
                This Agreement shall be binding upon and inure to the benefit of
                the
                parties hereto and their respective successors and assigns. The Company
                may not assign this Agreement or any rights or obligations hereunder
                without the prior written consent of the holders of Securities issued
                and
                issuable hereunder and under the Warrants including by way of a merger,
                consolidation, sale of all or substantially all of the Company’s assets
                and like transactions. The Investor may assign any of its rights
                or
                obligations hereunder.

            

    

     

    
      
        
        

      

      
        -25-

        
          

        

      

      
        
        

      

    

     

    
      	10.8  	
              No
                Third Party Beneficiaries.
                This Agreement is intended for the benefit of the parties hereto
                and their
                respective permitted successors and assigns, and is not for the benefit
                of, nor may any provision hereof be enforced by, any other
                Person.

            

    

     

    
      	10.9  	
              Survival.
                The representations and warranties of the Investor and the Company
                contained in Sections and 3 and 4 above and the applicable agreements
                and
                covenants set forth in Sections 4.25 above shall survive for four
                years
                after the Company makes such representations and warranties. Sections
                2.3,
                5, 8 and 10 shall survive termination or expiration of this Agreement.
                

            

    

     

    
      	10.10  	
              Further
                Assurances.
                Each party shall do and perform, or cause to be done and performed,
                all
                such further acts and things, and shall execute and deliver all such
                other
                agreements, certificates, instruments and documents, as any other
                party
                may reasonably request in order to carry out the intent and accomplish
                the
                purposes of this Agreement and the consummation of the transactions
                contemplated hereby. 

            

    

     

    
      	10.11  	
              Nature
                of Representations.
                The parties intend that each representation, warranty, and covenant
                contained herein shall have independent significance. If any party
                has
                breached any representation, warranty, or covenant contained herein
                in any
                respect, the fact that there exists another representation, warranty,
                or
                covenant relating to the same subject matter (regardless of the relative
                levels of specificity) which the party has not breached shall not
                detract
                from or mitigate the fact that the party is in breach of the first
                representation, warranty, or
                covenant.

            

    

     

    
      	10.12  	
              Confidentiality.
                Subject to Section 10.13 below, neither the Transaction Documents,
                the
                fact of their existence, nor their respective terms shall be disclosed
                to
                any party other than the Company and its advisors without the prior
                written consent of the Investor. In addition, the Company will not
                release
                and shall cause any of its shareholders not to release any information
                to
                the public regarding the Transaction Documents without the mutual
                agreement of both the Investor and the
                Company.

            

    

     

    
      	10.13  	
              Press
                Releases and Public Announcements.
                No party hereto shall issue any press release or make any public
                announcement relating to the Transaction Documents, the fact of their
                existence and their respective terms without the prior written approval
                of
                the other party hereto; provided,
                however,
                that the Company may make any disclosure it believes in good faith
                is
                required by applicable law or any listing or trading agreement concerning
                its publicly-traded securities. In such case, the Company will, prior
                to
                making such disclosure, advise the Investor as promptly as practicable
                of
                its intent to make such disclosure, allow the Investor reasonable
                time to
                comment on such disclosure and consider the views of the Investor
                in
                respect of such disclosure.

            

    

     

    IN
      WITNESS WHEREOF,
      the
      parties hereto have caused this Agreement to be duly executed and delivered
      as
      of the day and year first written above.

     

    
      	
              ACCBT
                Corp.

            	 	
              Brainstorm
                Cell Therapeutic Inc.

            
	 	 	 
	
              By:
                /s/ Chaim Lebovits

              
                

              

              Title: Director

            	 	
              By:
                /s/ Yoram Drucker

              
                

              

              
                Title:
                  Chief Operating
                  Officer

              

            
	 	 	
               

            

    

     

    
      
        
        

      

      
        -26-Exhibit
      10.2

     

    Warrant
      No.: [__] 

     

    Number
      of
      Shares of Common Stock: [_____]

     

    Date
      of
      Issuance: [] (“Issuance
      Date”)

     

    BRAINSTORM
      CELL THERAPEUTICS, INC.

     

    Common
      Stock Purchase Warrant

     

    BRAINSTORM
      CELL THERAPEUTICS, INC.,
      a
      Delaware corporation (“Company”),
      hereby certifies that, for good and valuable consideration, the receipt and
      sufficiency of which are hereby acknowledged, ACCBT
      CORP.,
      the
      registered holder hereof or its permitted assigns ( “Holder”),
      is
      entitled, subject to the terms set forth below, to purchase from the Company,
      at
      the Exercise Price (as defined below) then in effect, upon surrender of this
      Warrant Common Stock (including any Warrants to Purchase Common Stock issued
      in
      exchange, transfer or replacement hereof, “Warrant”),
      at
      any time or times on or after the date hereof, but not after 11:59 p.m., Eastern
      Standard Time, on the Expiration Date (as defined below), [________] fully
      paid
      nonassessable shares of Common Stock (as defined below) (“Warrant
      Shares”).
      Except as otherwise defined herein, capitalized terms in this Warrant shall
      have
      the meanings set forth in Section 1.
      This
      Warrant is one of a series of warrants to purchase Common Stock (“Warrants”)
      issued
      pursuant to that certain Subscription Agreement, dated as of July 2, 2007
      (“Subscription
      Date”),
      by
      and between the Company and ACCBT Corp. (“Investor”)
      referred to therein (the “Subscription
      Agreement”).

     

    1. DEFINITIONS

     

    1.1        
      “$”
means
      United States Dollars.

     

    1.2        
      “Board”
means
      the board of directors of the Company.

     

    1.3        
      “Bloomberg”
means
      Bloomberg Financial Markets.

     

    1.4        
      “Business
      Day”
means
      any day other than Saturday, Sunday or other day on which commercial banks
      in
      the City of New York are authorized or required by law to remain
      closed.

     

    1.5        
      “Closing
      Bid Price”
and
      “Closing
      Sale Price”
means,
      for any security as of any date, the last closing bid price and last closing
      trade price, respectively, for such security on the Principal Market, as
      reported by Bloomberg, or, if the Principal Market begins to operate on an
      extended hours basis and does not designate the closing bid price or the closing
      trade price, as the case may be, then the last bid price or last trade price,
      respectively, of such security prior to 4:00 p.m., New York Time, as reported
      by
      Bloomberg, or, if the Principal Market is not the principal securities exchange
      or trading market for such security, the last closing bid price or last trade
      price, respectively, of such security on the principal securities exchange
      or
      trading market where such security is listed or traded as reported by Bloomberg,
      or if the foregoing do not apply, the last closing bid price or last trade
      price, respectively, of such security in the over-the-counter market on the
      electronic bulletin board for such security as reported by Bloomberg, or, if
      no
      closing bid price or last trade price, respectively, is reported for such
      security by Bloomberg, the average of the bid prices, or the ask prices,
      respectively, of any market makers for such security as reported in the “pink
      sheets” by Pink Sheets LLC (formerly the National Quotation Bureau, Inc.). If
      the Closing Bid Price or the Closing Sale Price cannot be calculated for a
      security on a particular date on any of the foregoing bases, the Closing Bid
      Price or the Closing Sale Price, as the case may be, of such security on such
      date shall be the fair market value as mutually determined by the Company and
      the Holder. All such determinations to be appropriately adjusted for any stock
      dividend, stock split, stock combination or other similar transaction during
      the
      applicable calculation period. 

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    1.6        
      “Common
      Stock”
means
      (i) shares of common stock in the capital of the Company par value $0.00005,
      and
      (ii) any share capital into which such Common Stock shall have been changed
      or any share capital resulting from a reclassification of such Common
      Stock.

     

    1.7         “Convertible
      Securities”
means
      any
      shares or securities or instruments (other than Options) directly or indirectly
      convertible into or exercisable or exchangeable for Common Shares.

     

    1.8         “Excluded
      Securities”
means
      (i) shares of Common Stock issued pursuant to a transaction described in Section
      3.3
      below;
      (ii)
      shares of Common Stock issued or deemed issued to employees, consultants,
      officers or directors (if in transactions with primarily non-financing purposes)
      of this Company pursuant to a board approved stock option plan and in an
      aggregate amount of up to [10%] of the shares of common Stock from time to
      time
      calculated on a fully-diluted as converted basis; (iii) shares of Common Stock
      issued pursuant to other Warrants ; and (iv) shares of Common Stock issued
      pursuant to other conversion of principal (but not interest) of any Convertible
      Securities outstanding as of the Issuance Date 

     

    1.9        
      “Expiration
      Date”
means
      November 5, 2011. 

     

    1.10      
      “Options”
means
      any
      rights, warrants or options to subscribe for or purchase Common Shares or
      Convertible Securities.

     

    1.11      
      “Principal
      Market”
means
      the NASD’s OTC Bulletin Board.

     

    2. EXERCISE
      OF WARRANT 

     

    2.1        
      Mechanics
      of Exercise.
      Subject
      to the terms and conditions hereof, this Warrant may be exercised by the Holder
      on any day on or after the date hereof, in whole or in part, by (i) delivery
      of
      a written notice, in the form attached hereto as Exhibit A (“Exercise
      Notice”),
      of
      the Holder’s election to exercise this Warrant and (ii) (A) payment to the
      Company of an amount equal to the applicable Exercise Price multiplied by the
      number of Warrant Shares as to which this Warrant is being exercised
      (“Aggregate
      Exercise Price”)
      in
      cash or wire transfer of immediately available funds or (B) by notifying the
      Company that this Warrant is being exercised in a Cashless Exercise pursuant
      to
      and subject to the conditions set forth in Section 2.3
      below.
      The
      Holder shall not be required to deliver the original Warrant in order to effect
      an exercise hereunder. Execution and delivery of the Exercise Notice with
      respect to less than all of the Warrant Shares shall have the same effect as
      cancellation of the original Warrant and issuance of a new Warrant evidencing
      the right to purchase the remaining number of Warrant Shares. On or before
      the
      first Business Day following the date on which the Company has received each
      of
      the Exercise Notice and the Aggregate Exercise Price (or notice of a Cashless
      Exercise) (“Exercise
      Delivery Documents”),
      the
      Company shall transmit by facsimile an acknowledgment of confirmation of receipt
      of the Exercise Delivery Documents to the Holder and the Company’s transfer
      agent (“Transfer
      Agent”).
      On or
      before the third Business Day following the date on which the Company has
      received all of the Exercise Delivery Documents (“Share
      Delivery Date”),
      the
      Company shall issue and dispatch by overnight courier to the address as
      specified in the Exercise Notice, a certificate, registered in the Company’s
      share register in the name of the Holder or its designee, for the number of
      shares of Common Stock to which the Holder is entitled pursuant to such
      exercise. Upon delivery of the Exercise Notice and Aggregate Exercise Price
      referred to in clause (ii)(A) above or notification to the Company of a Cashless
      Exercise referred to in Section 2.3
      below,
      the
      Holder shall be deemed for all corporate purposes to have become the holder
      of
      record of the Warrant Shares with respect to which this Warrant has been
      exercised, irrespective of the date of delivery of the certificates evidencing
      such Warrant Shares. If this Warrant is submitted in connection with any
      exercise pursuant to this Section 2.1
      and the
      number of Warrant Shares represented by this Warrant submitted for exercise
      is
      greater than the number of Warrant Shares being acquired upon an exercise,
      then
      the Company shall as soon as practicable and in no event later than three
      Business Days after any exercise and at its own expense, issue a new Warrant
      (in
      accordance with Section 5.4
      below)
      representing the right to purchase the number of Warrant Shares purchasable
      immediately prior to such exercise under this Warrant, less the number of
      Warrant Shares with respect to which this Warrant is exercised. No fractional
      shares of Common Stock are to be issued upon the exercise of this Warrant,
      but
      rather the number of shares of Common Stock to be issued shall be rounded up
      to
      the nearest whole number. The Company shall pay any and all taxes which may
      be
      payable with respect to the issuance and delivery of Warrant Shares upon
      exercise of this Warrant.
      Notwithstanding anything to the contrary, a Cashless Exercise may only be
      utilized with respect to up to and including 50% of the Warrant Shares, with
      the
      payment of the exercise price for all other Warrant Shares being in the form
      of
      cash or wire transfer of immediately available funds. Subject to the foregoing,
      the Holder shall be entitled to determine which of the Warrant Shares shall
      be
      considered to qualify for Cashless Exercise.

     

    
      
         

      

      
        -
          2
          -

        
          

        

      

      
         

      

    

     

    2.2        
      Exercise
      Price.
      For
      purposes of this Warrant, “Exercise
      Price”
means
      [$0.20, $0.29, $0.36] subject to adjustment as provided herein.

     

    2.3        
      Cashless
      Exercise.
      The
      Holder may, in its sole discretion, exercise this Warrant with respect to up
      to
      50% of the number of shares of Common Stock issuable hereunder and, in lieu
      of
      making the cash payment otherwise contemplated to be made to the Company upon
      such exercise in payment of the Aggregate Exercise Price, elect instead to
      receive upon such exercise the “Net Number” of shares of Common Stock determined
      according to the following formula (“Cashless
      Exercise”):

     

    Net
      Number = (A
      x
      B) - (A x C)

    B

     

    
      
         

      

      
        -
          3
          -

        
          

        

      

      
         

      

    

    For
      purposes of the foregoing formula:

     

    A=
      the
      total number of shares with respect to which this Warrant is then being
      exercised.

     

    B=
      the
      Closing Sale Price of the shares of Common Stock (as reported by Bloomberg)
      on
      the date immediately preceding the date of the Exercise Notice.

     

    C=
      the
      Exercise Price then in effect for the applicable Warrant Shares at the time
      of
      such exercise.

     

    2.4        
      Disputes.
      In the
      case of a dispute as to the determination of the Exercise Price or the
      arithmetic calculation of the Warrant Shares, the Company shall promptly issue
      to the Holder the number of Warrant Shares that are not disputed.

     

    2.5       
      Insufficient
      Authorized Shares.
      If at
      any time while any of the Warrants remain outstanding the Company does not
      have
      a sufficient number of authorized and unreserved shares of Common Stock to
      satisfy its obligation to reserve for issuance upon exercise of the Warrants
      at
      least a number of shares of Common Stock equal to 110% (“Required
      Reserve Amount”)
      of the
      number of shares of Common Stock as shall from time to time be necessary to
      effect the exercise of all of the Warrants then outstanding (“Authorized
      Share Failure”),
      then
      the Company shall immediately take all action necessary to increase the
      Company’s authorized shares of Common Stock to an amount sufficient to allow the
      Company to reserve the Required Reserve Amount for the Warrants then
      outstanding. Without limiting the generality of the foregoing sentence, as
      soon
      as practicable after the date of the occurrence of an Authorized Share Failure,
      but in no event later than sixty (60) days after the occurrence of such
      Authorized Share Failure, the Company shall hold a meeting of its stockholders
      for the approval of an increase in the number of authorized shares of Common
      Stock. In connection with such meeting, the Company shall provide each
      stockholder with a proxy statement and shall use its best efforts to solicit
      its
      stockholders’ approval of such increase in authorized shares of Common Stock and
      to cause its board of directors to recommend to the stockholders that they
      approve such proposal.

     

    3. ADJUSTMENT
      OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES 

     

    The
      Exercise Price and the number of Warrant Shares shall be adjusted from time
      to
      time as follows:

     

    3.1        
      Full
      Ratchet Adjustment of Exercise Price upon Issuance of Common
      Stock.
      After
      the Closing Date, if the Company issues any shares of Common Stock in a bona
      fide offering of its securities (including the issuance or sale of shares of
      Common Stock owned or held by or for the account of the Company, but excluding
      shares of Common Stock deemed to have been issued or sold by the Company in
      connection with any Excluded Securities) for a consideration per share
      (“New
      Issuance Price”)
      less
      than the Exercise Price in effect immediately prior to such issue or sale (the
      foregoing a “Dilutive
      Issuance”),
      then
      immediately after such Dilutive Issuance, the Exercise Price then in effect
      shall be reduced to an amount equal to the New Issuance Price. 

     

    
      
         

      

      
        -
          4
          -

        
          

        

      

      
         

      

    

     

    3.2        
      Provisions
      Applicable to Exercise Price Adjustments.
      For
      purposes of determining the adjusted Exercise Price under Section 3.1
      above,
      the
      following provisions shall apply: 

     

    3.2.1          
      Issuance
      of Options.
      If the
      Company in any manner grants or sells any Options (other than any Excluded
      Securities) and the lowest price per share for which one share of Common Stock
      is issuable upon the exercise of any such Option or upon conversion or exchange
      or exercise of any Convertible Securities issuable upon exercise of such Option
      is less than the Exercise Price, then such share of Common Stock shall be deemed
      to be outstanding and to have been issued and sold by the Company at the time
      of
      the granting or sale of such Option for such price per share. For purposes
      of
      this Section 3.2.1,
      the
“lowest price per share for which one share of Common Stock is issuable upon
      the
      exercise of any such Option or upon conversion or exchange or exercise of any
      Convertible Securities issuable upon exercise of such Option” shall be equal to
      the sum of the lowest amounts of consideration (if any) received or receivable
      by the Company with respect to any one share of Common Stock upon granting
      or
      sale of the Option, upon exercise of the Option and upon conversion or exchange
      or exercise of any Convertible Security issuable upon exercise of such
      Option.

     

    3.2.2          
      Issuance
      of Convertible Securities.
      If the
      Company in any manner issues or sells any Convertible Securities (other than
      Excluded Securities) and the lowest price per share for which one share of
      Common Stock is issuable upon such conversion or exchange or exercise thereof
      is
      less than the Exercise Price, then such share of Common Stock shall be deemed
      to
      be outstanding and to have been issued and sold by the Company at the time
      of
      the issuance of sale of such Convertible Securities for such price per share.
      For the purposes of this Section 3.2.2,
      the
“price per share for which one share of Common Stock is issuable upon such
      conversion or exchange or exercise” shall be equal to the sum of the lowest
      amounts of consideration (if any) received or receivable by the Company with
      respect to any one share of Common Stock upon the issuance or sale of the
      Convertible Security and upon the conversion or exchange or exercise of such
      Convertible Security.

     

    3.2.3          Change
      in Option Price or Rate of Conversion.
      If the
      purchase price provided for in any Options (other than Excluded Securities),
      the
      additional consideration, if any, payable upon the issue, conversion, exchange
      or exercise of any Convertible Securities, or the rate at which any Convertible
      Securities (other than Excluded Securities) are convertible into or exchangeable
      or exercisable for Common Stock is changed, the Exercise Price in effect at
      the
      time of such change shall be adjusted to the Exercise Price which would have
      been in effect at such time had such Options or Convertible Securities provided
      for such changed purchase price, additional consideration or changed conversion
      rate, as the case may be, at the time initially granted, issued or sold. For
      purposes of this Section 3.2.3,
      if the
      terms of any Option or Convertible Security that was outstanding as of the
      Closing Date are changed in the manner described in the immediately preceding
      sentence, then such Option or Convertible Security and the Common Stock deemed
      issuable upon exercise, conversion or exchange thereof shall be deemed to have
      been issued as of the date of such change. No adjustment shall be made if such
      adjustment would result in an increase of the Exercise Price then in
      effect.

     

    
      
         

      

      
        -
          5
          -

        
          

        

      

      
         

      

    

     

    3.2.4          
      Record
      Date.
      If the
      Company takes a record of the holders of Common Stock for the purpose of
      entitling them (i) to receive a dividend or other distribution payable in Common
      Stock, Options or in Convertible Securities or (ii) to subscribe for or purchase
      Common Stock, Options or Convertible Securities, then such record date will
      be
      deemed to be the date of the issue or sale of the Common Stock deemed to have
      been issued or sold upon the declaration of such dividend or the making of
      such
      other distribution or the date of the granting of such right of subscription
      or
      purchase, as the case may be.

     

    3.2.5          
      Dividends.
      In case
      the Company shall declare a dividend or make any other distribution upon any
      stock of the Company (other than the Common Stock) payable in Common Stock,
      Options or Convertible Securities, then any Common Stock, Options or Convertible
      Securities, as the case may be, issuable in payment of such dividend or
      distribution shall be deemed to have been issued or sold without
      consideration.

     

    3.2.6          Calculation
      of Consideration.
      In case
      any shares of Common Stock, Options or Convertible Securities shall be issued
      or
      sold for cash, the consideration received therefor shall be deemed to be the
      net
      amount received by the Company therefor, after deduction therefrom of any
      expenses incurred or any underwriting commissions or concessions paid or allowed
      by the Company in connection therewith. In case any shares of Common Stock,
      Options or Convertible Securities shall be issued or sold for a consideration
      other than cash, the amount of the consideration other than cash received by
      the
      Company shall be deemed to be the fair value of such consideration as determined
      in good faith by the Board, after deduction of any expenses incurred or any
      underwriting commissions or concessions paid or allowed by the Company in
      connection therewith. In case any Options shall be issued in connection with
      the
      issuance and sale of other securities of the Company, together comprising one
      integral transaction in which no specific consideration is allocated to such
      Options by the parties thereto, such Options shall be deemed to have been issued
      for such consideration as determined in good faith by the Board. If Common
      Stock, Options or Convertible Securities shall be issued or sold by the Company
      and, in connection therewith, other Options or Convertible Securities
      (“Additional
      Rights”)
      are
      issued, then the consideration received or deemed to be received by the Company
      shall be reduced by the fair market value of the Additional Rights (as
      determined using the Black-Scholes option pricing model or another method
      mutually agreed to by the Company and the Holder). The Board shall respond
      promptly, in writing, to an inquiry by the Holder as to the fair market value
      of
      the Additional Rights.

     

    
      
         

      

      
        -
          6
          -

        
          

        

      

      
         

      

    

     

    3.3       
      Adjustment
      upon Subdivision or Combination of Common Stock.
      If the
      Company at any time on or after the date hereof subdivides (by any stock split,
      stock dividend, recapitalization or otherwise) one or more classes of its
      outstanding shares of Common Stock into a greater number of shares, the Exercise
      Price in effect immediately prior to such subdivision will be proportionately
      reduced and the number of Warrant Shares will be proportionately increased.
      If
      the Company at any time on or after the Closing Date combines (by combination,
      reverse stock split or otherwise) one or more classes of its outstanding shares
      of Common Stock into a smaller number of shares, the Exercise Price in effect
      immediately prior to such combination will be proportionately increased and
      the
      number of Warrant Shares will be proportionately decreased. Any adjustment
      under
      this Section 3.3
      shall
      become effective at the close of business on the date the subdivision or
      combination becomes effective.

     

    4. NONCIRCUMVENTION

     

    The
      Company hereby covenants and agrees that the Company will not, by amendment
      of
      its Certificate of Incorporation, Bylaws (as such terms are defined in the
      Subscription Agreement) or through any reorganization, transfer of assets,
      consolidation, merger, scheme of arrangement, dissolution, issue or sale of
      securities, or any other voluntary action, avoid or seek to avoid the observance
      or performance of any of the terms of this Warrant, and will at all times in
      good faith carry out all the provisions of this Warrant and take all action
      as
      may be required to protect the rights of the Holder. Without limiting the
      generality of the foregoing, the Company (i) shall not increase the par
      value of any shares of Common Stock receivable upon the exercise of this Warrant
      above the Exercise Price then in effect, (ii) shall take all such actions
      as may be necessary or appropriate in order that the Company may validly and
      legally issue fully paid and nonassessable shares of Common Stock upon the
      exercise of this Warrant, and (iii) shall, so long as any of the Warrants are
      outstanding, take all action necessary to reserve and keep available out of
      its
      authorized and unissued shares of Common Stock, solely for the purpose of
      effecting the exercise of the Warrants, 110% of the number of shares of Common
      Stock as shall from time to time be necessary to effect the exercise of the
      Warrants then outstanding. 

     

    5. REISSUANCE
      OF WARRANTS

     

    5.1        Transfer
      of Warrant.
      If this
      Warrant is to be transferred, the Holder shall surrender this Warrant to the
      Company, whereupon the Company will forthwith issue and deliver upon the order
      of the Holder a new Warrant (in accordance with Section 5.4
      below),
      registered as the Holder may request, representing the right to purchase the
      number of Warrant Shares being transferred by the Holder and, if less then
      the
      total number of Warrant Shares then underlying this Warrant is being
      transferred, a new Warrant (in accordance with Section 5.4
      below)
      to the
      Holder representing the right to purchase the number of Warrant Shares not
      being
      transferred.

     

    5.2       
      Lost,
      Stolen or Mutilated Warrant.
      Upon
      receipt by the Company of evidence reasonably satisfactory to the Company of
      the
      loss, theft, destruction or mutilation of this Warrant, and, in the case of
      loss, theft or destruction, of any indemnification undertaking by the Holder
      to
      the Company in customary form and, in the case of mutilation, upon surrender
      and
      cancellation of this Warrant, the Company shall execute and deliver to the
      Holder a new Warrant (in accordance with Section 5.4
      below)
      representing the right to purchase the Warrant Shares then underlying this
      Warrant.

     

    
      
         

      

      
        -
          7
          -

        
          

        

      

      
         

      

    

     

    5.3        
      Exchangeable
      for Multiple Warrants.
      This
      Warrant is exchangeable, upon the surrender hereof by the Holder at the
      principal office of the Company, for a new Warrant or Warrants (in accordance
      with Section 5.4
      below)
      representing in the aggregate the right to purchase the number of Warrant Shares
      then underlying this Warrant, and each such new Warrant will represent the
      right
      to purchase such portion of such Warrant Shares as is designated by the Holder
      at the time of such surrender; provided, however, that no Warrants for
      fractional shares of Common Stock shall be given.

     

    5.4        
      Issuance
      of New Warrants.
      Whenever the Company is required to issue a new Warrant pursuant to the terms
      of
      this Warrant, such new Warrant (i) shall be of like tenor with this Warrant,
      (ii) shall represent, as indicated on the face of such new Warrant, the right
      to
      purchase the Warrant Shares then underlying this Warrant (or in the case of
      a
      new Warrant being issued pursuant to Section 5.1
      or
      Section 5.3,
      the
      Warrant Shares designated by the Holder which, when added to the number of
      shares of Common Stock underlying the other new Warrants issued in connection
      with such issuance, does not exceed the number of Warrant Shares then underlying
      this Warrant), (iii) shall have an issuance date, as indicated on the face
      of
      such new Warrant which is the same as the Issuance Date, and (iv) shall have
      the
      same rights and conditions as this Warrant.

     

    6. NOTICES
      

     

    Whenever
      notice is required to be given under this Warrant, unless otherwise provided
      herein, such notice shall be given in accordance with Section 10.6 of the
      Subscription Agreement. The Company shall provide the Holder with prompt written
      notice of all actions taken pursuant to this Warrant, including in reasonable
      detail a description of such action and the reason therefore. Without limiting
      the generality of the foregoing, the Company will give written notice to the
      Holder (i) immediately upon any adjustment of the Exercise Price, setting forth
      in reasonable detail, and certifying, the calculation of such adjustment and
      (ii) at least fifteen days prior to the date on which the Company closes its
      books or takes a record (A) with respect to any dividend or distribution upon
      the shares of Common Stock, (B) with respect to any grants, issuances or sales
      of any Options, Convertible Securities or rights to purchase stock, warrants,
      securities or other property to holders of shares of Common Stock.

     

    7. AMENDMENT
      AND WAIVER

     

    Except
      as
      otherwise provided herein, the provisions of this Warrant may be amended and
      the
      Company may take any action herein prohibited, or omit to perform any act herein
      required to be performed by it, only if the Company has obtained the written
      consent of the Holder.

     

    8. GOVERNING
      LAW

     

    This
      Agreement shall be governed by, and construed in accordance with, the internal
      laws of the State of Israel without regard to the choice of law principles
      thereof.

     

    9. CONSTRUCTION;
      HEADINGS 

     

    This
      Warrant shall be deemed to be jointly drafted by the Company and all the Holder
      and shall not be construed against any person as the drafter hereof. The
      headings of this Warrant are for convenience of reference and shall not form
      part of, or affect the interpretation of, this Warrant.

     

    
      
         

      

      
        -
          8
          -

        
          

        

      

      
         

      

    

     

    10. TRANSFER 

     

    This
      Warrant may be offered for sale, sold, transferred or assigned without the
      consent of the Company. 

     

    IN
      WITNESS WHEREOF,
      the
      Company has caused this Warrant to Purchase Common Stock to be duly executed
      as
      of the Issuance Date set out above.

     

    
      	 	 	 
	 	BRAINSTORM
              CELL THERAPEUTICS, INC.
	 
 	 
 	 
 
	
            	By:  	
            
	 	
              
Name:
	 	Title:

 

    
      
         

      

      
        -
          9
          -

        
          

        

      

      
         

      

    

    EXHIBIT
      A

     

    EXERCISE
      NOTICE

     

    TO
      BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS

     

    WARRANT
      TO PURCHASE COMMON STOCK

     

    BRAINSTORM
      CELL THERAPEUTICS, INC.

     

    The
      undersigned holder hereby exercises the right to purchase _________________
      of
      the shares of Common Stock (“Warrant
      Shares”)
      of
      BRAINSTORM CELL THERAPEUTICS, INC., a Delaware corporation (“Company”),
      evidenced by the attached Warrant to Purchase Common Stock (“Warrant”).
      Capitalized terms used herein and not otherwise defined shall have the
      respective meanings set forth in the Warrant.

     

    
      	
              1.

            	
              Form
                of Exercise Price.
                The Holder intends that payment of the Exercise Price shall be made
                as:

            

    

     

    __________ a
“Cash
      Exercise” with respect to _________________ Warrant Shares; and/or

     

    __________ a
      “Cashless Exercise” with respect to _______________ Warrant Shares.

     

    
      	2.	
              Payment
                of Exercise Price.
                In the event that the holder has elected a Cash Exercise with respect
                to
                some or all of the Warrant Shares to be issued pursuant hereto, the
                holder
                shall pay the Aggregate Exercise Price in the sum of $___________________
                to the Company in accordance with the terms of the
                Warrant.

            

    

     

    
      	3.	
              Delivery
                of Warrant Shares.
                The Company shall deliver to the holder __________ Warrant Shares
                in
                accordance with the terms of the
                Warrant.

            

    

     

    Date:
      _______________ __, ______

     

    Name
      of
      Registered Holder

     

    
      	 	 	 	 	 
	By:	
            	 	 	
            
	 	Name:	 	 	
            
	 	Title:	 	 	
            

    

      

    
      
         

      

      
        -
          10
          -

        
          

        

      

      
         

      

    

     

    ACKNOWLEDGMENT

     

    The
      Company hereby acknowledges this Exercise Notice and hereby directs [Insert
      Name
      of Transfer Agent] to issue the above indicated number of shares of Common
      Stock
      in accordance with the Transfer Agent Instructions dated _______________ from
      the Company and acknowledged and agreed to by [Insert Name of Transfer
      Agent].

     

    
      BRAINSTORM
        CELL THERAPEUTICS, INC.

       

    

    
      
        	 	 	 	 	 
	By:	
              	 	 	
              
	 	Name:	 	 	
              
	 	Title:	 	 	
              

      

       

      
        
           

        

        
          -
            11
            -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}]]